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ABSTRACT 
Obesity and type 2 diabetes, with associated chronic inflammation and metabolic syndrome, are 
important risk factors for malignancies. In particular, meta-analyses of clinical studies suggest 
that hyperinsulinemia is a major cancer risk factor. Increased levels of circulating insulin may 
promote tumor progression by activating insulin (INSR) and IGF1 (IGF1R) receptors, that are 
frequently overexpressed in cancer cells. Moreover, in obese patients, insulin can synergize with 
inflammation to promote proliferation, survival, and dissemination of cancer cells. 
The kinase AKT/PKB is a key mediator of the proliferative and survival effects of insulin on 
tumor cells. In addition, Akt directly links hyperinsulinemia to inflammation through activation 
of NF-kB signaling. The tumor suppressor DAB2IP (Disabled homolog 2 interacting protein), 
also known as AIP1 (ASK1 interacting protein), binds and inhibits PI3K-p85, limiting AKT 
activation in response to various stimuli. DAB2IP also binds directly to AKT1, possibly 
contributing to its inhibition. 
In addition to its action on AKT, DAB2IP modulates multiple extracellular signals involved in 
cancer progression, thus acting as a tumor suppressor. Its expression is frequently reduced by 
methylation in tumors, but other molecular mechanisms of DAB2IP inactivation in cancer have 
been identified. One of such mechanisms is interaction with mutant p53 proteins. 
Point mutation of p53 is a frequent event and a significant factor in cancer development and 
progression. Mutant p53 proteins (mutp53) are very stable, and acquire oncogenic properties 
(gain of function) that can increase proliferation, survival and metastatic potential of tumor cells. 
In this thesis, I demonstrate that mutant p53, by binding DAB2IP, promotes insulin-induced 
AKT activation in triple negative breast cancer and androgen-independent prostate cancer cell 
lines, with cell-autonomous effects on proliferation and survival. Using a decoy protein to 
displace the mutp53-DAB2IP interaction, I showed that formation of this cytoplasmic complex is 
necessary for the enhanced response to insulin observed in mutant p53-bearing cancer cells. 
Together, the evidence reported in this Thesis underline a specific gain of function of mutp53 in 
the response of cancer cells to insulin stimulation, offering an additional perspective to 
understand the complex relationship between hyperinsulinemia and cancer evolution. 
 
 
2 
INTRODUCTION 
 
1. CANCER, OBESITY AND HYPERINSULINEMIA 
 
1.1 The insulin-cancer connection 
Excess body weight (EBW) in the overweight and obese is a well recognized risk factor for the 
development of cardiovascular disease and diabetes mellitus, but less well appreciated as a risk 
factor for several common adult cancers (Renehan and Howell, 2005). Only in 2002 the 
International Agency for Cancer Research stated that there is “now sufficient evidence that 
excess body weight is an avoidable cause of excess cancers including colorectal, endometrial, 
post-menopausal breast, kidney, pancreatic, oesophagealand, aggressive prostate cancers” 
(Vainio, H. and Bianchini, 2002). 
Tumorigenesis is a multistep process involving the accumulation of genetic and epigenetic 
changes in several genes (Bernards and Weinberg, 2002), as well as multiple alterations in the 
regulatory circuits that finely modulate proliferation and homeostasis of normal cells (Hanahan 
and Weinberg, 2000).  Thus, in addition to various pathological events, tumorigenesis and cancer 
progression strongly depend on extrinsic factors secreted by cancer cells themselves or by 
stromal cells. Those secreted factors, i.e. cytokines/chemokines, proteases, growth and 
angiogenic factors, as well as other molecules having an oncogenic effect, may regulate the 
crosstalk between stroma-cancer cells and tumor microenvironment promoting cancer initiation 
and progression. Several biological pathways, such as Smad, PI3K, JAK/STAT, NF-kB, MAPK, 
CXCR2 and IL-1 have been indicated as able to orchestrate this complex crosstalk system 
(Coppè et al., 2011) (He and Karin, 2011). 
 
Insulin, insulin-like growth factors (IGFs), sexual hormones, and cytokines can boost cancer 
growth, linking obesity to cancer (Roberts et al., 2010). Inflammatory cytokines, such as 
adipokines, play an important role in tumor progression (Palomer et al., 2005). The amount of 
adiponectin, adipokine mainly produced by adipose tissue, is inversely proportional to the body 
mass index (BMI), it has an antiproliferative, anti-angiogenic and pro-apoptotic role, so low 
levels of this cytokine, predominant condition in obese individuals, correlates with a high risk of 
developing cancer (Roberts et al., 2010). Insulin and IGF-1-induced pathways are strictly linked 
to obesity and work to prohibit apoptosis and promote cell proliferation. Hyperinsulinemia might 
contribute to cancer development through the growth-promoting effect of elevated levels of the 
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hormone. Indeed, the excessive caloric intake of individuals with obesity leads to desensitization 
of tissues against insulin, resulting in insulin resistance, leading to increased production of 
insulin to restore normal levels of glucose. The tissues fail to metabolize the excess produced 
glucose and the pancreas secretes large amounts of insulin, promoting the hyperinsulinemic 
condition (Wysocki and Wierusz-Wysocka, 2010). Moreover, hyperinsulinemia in obese 
subjects is fueled by the catabolism of fatty acids. Obesity is, in fact, characterized by an 
increase in the levels of non-esterified fatty acids released by adipose tissue, and these are 
mainly catabolized to produce glucose and energy, causing hyperglycaemia (Karpe et al., 2011). 
Hyperinsulinemia triggers the insulin-IGF pathway, a complex pathway that includes insulin, 
IGF-1, and IGF-2 (three ligands), along with six receptors (insulin receptor IR α and β, IGF-1 
receptor, IGF-2 receptor, hybrid IGF-1R/IR α, and hybrid IGF-1R/IR β) and seven IGF-binding 
proteins (IGFBPs) (Sridhar and Goodwin, 2009). It is hypothesized that the increased level of 
insulin reduces the amount of IGFBPs, which leads to an increase in the level of IGF-1 and a 
change in cell environment which promotes tumor growth (Renehan et al., 2006). Indeed, growth 
hormone, which is regulated by insulin, stimulates production of IGF-1 and IGFBP-3 
(Clemmons, 1998). Insulin controls many aspects of metabolism, growth and survival in a wide 
range of mammalian tissues (Nakae et al. 2001). Insulin signalling also contributes to regulation 
of lifespan (Narasimhan et al., 2009), and has been implicated in cancer (Pollak et al., 2008). 
High circulating levels of insulin and other insulin-like growth factors promote cellular 
proliferation and affect programmed cell death (apoptosis), increasing the risk of cancer 
(Giovannucci et al., 2010). Indeed, recent papers report that patients with hyperglycemia show 
decreased cancer-specific survival respect to patients with normoglycemic plasma levels (Joost, 
2014). Compensatory hyperinsulinemia, also consequent to insulin resistance, is the major 
common factor characterizing a variety of metabolic diseases such as obesity, type 2 diabetes 
mellitus, and metabolic syndrome. Indeed, several epidemiological studies reveal that patients 
with these disorders show increased risk to develop a variety of malignancies (Joost, 
2014)(Cantiello et al., 2015). 
 
1.2 Insulin receptors 
Several studies have convincingly shown that the insulin receptor (IR) pathway is more directly 
and intimately involved in cancer development and progression than previously thought. 
Overactivation of this pathway by both insulin and IGF-II is common in cancer cells, particularly 
in dedifferentiated/stem-like cells, and may represent an important factor of resistance to various 
anti-cancer drugs (Belfiore, 2007). Additionally, cancer cells are often more responsive to insulin 
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due to Insulin Receptors (IRs) overespression, obtaining a selective advantage relative to non-
malignant cells (Malaguarnera and Belfiore, 2011). 
 
The insulin receptor (IR) is a tetrameric protein that consists of two extracellular α-subunits and 
two intracellular β-subunits. The α subunit of the receptor contains the ligand binding sites, 
usually located at a cysteine-rich domain on the extracellular region (Kristensen et al., 1995) 
(Whittaker and Whittaker, 2005). Insulin binding to the α-subunit leads to increase flexibility of 
the activation loop to allow ATP to enter the catalytic site and stabilize the activation loop in the 
active conformation by auto-phosphorylation of the β-subunits in various sites. The β subunits of 
IR include a large cytoplasmic region with tyrosine kinase activity. Auto-phosphorylation leads 
to interaction and phosphorylation  of insulin receptor substrates (IRS-1 to IRS-4), which are 
generally viewed as the most specific for insulin signaling; and Shc proteins (Pelicci, G, et al. 
1992), Gab-1 (Holgado-Madruga et al., 1996) and p62dok (Carpino et al., 1997). Indeed, activated 
IRS proteins interact with Grb-2 (growth factor receptor binding protein 2), the tyrosine 
phosphatase SHP-2 and with the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K). A 
typical IRS protein contains a PH domain, which targets the protein in plasma membrane 
(Yenush et al., 1996), and a PTB domain, which recognizes the phosphotyrosine in the amino 
acid sequence asparagine-proline amino acid-phosphotyrosine (NPXpY), often presents in 
tyrosine kinase receptors, including β-subunit of insulin receptor (Eck et al., 1996)(Wolf et al., 
1995). The specificity of the Grb-2, SHP-2 or PI3K binding is regulated by the few amino acids 
COOH-terminal to the phosphotyrosine. The SH2 domains of PI3-kinase recognize at least four 
pYMXM motifs in tyrosine-phosphorylated IRS-1. The SH2 domain of the adaptor protein Grb-
2 and the SH2 domain of the phosphotyrosine phosphatase SHP-2 bind other sequences, 
including pYVNI, pYIDL, and pYASI sequences (Virkamäki et al., 1999). 
 
Figure 1: Protein–protein interaction 
domains involved in insulin signal 
transduction. 
IRS protein contains a PH domain and a 
PTB domain, which binds to NPXpY 
motif in the β subunit of the insulin 
receptor. SH2 domains of SH2 adaptors 
and SH2 enzymes bind to multiple 
phosphotyrosines of IRS proteins. SH2 
adaptors frequently possess SH3 
domains that recognize PXXP motifs of 
other intracellular proteins, leading to 
further downstream signal transduction 
(Virakami et al., 1999). 
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Alternative splicing of the IR exon 11 results in the expression of two isoforms: IRA (lacking 
exon 11) and IRB (including exon 11) (Seino and Bell, 1989). The relative abundance of IRA 
and IRB isoforms displays tissue specificity in both humans and rats (Moller et al., 
1989)(Goldstein and Dudley, 1990) and is also regulated during development and cell 
differentiation, with IRA representing the predominant isoform in fetal and highly proliferative 
tissues (Frasca et al., 1999). In breast, colon, lung, ovary and thyroid carcinomas, the A isoform 
is more present than the B isoform (Belfiore and Malaguarnera, 2011).  
 
 
 
 
Some studies have indicated that IR-B may signal more efficiently to metabolic endpoints, and 
IR-A to mitogenic endpoints (Belfiore et al., 2009). It has also been suggested that IR-A and IR-
B localise to different lipid raft microdomains, within which distinct signalling complexes are 
assembled (Leibiger et al., 2010). Tyrosine phosphorylation of IRS, as described above, creates 
binding sites for SH2 domains of various proteins, notably the regulatory subunits of class Ia 
PI3Ks and the adaptor Grb2. Indeed, the IR activation by insulin binding leads to the activation 
of two main cascades: the MAPK and the PI3K/Akt pathways. 
 
1.3 Insulin activated pathways 
1.3.1 Ras–mitogen-activated protein kinase (MAPK) cascade 
IR-A activation by insulin leads to the predominance of growth and proliferative signals through 
the phosphorylation of tyrosine residues into cytoplasmic IRS1/2 and Shc proteins. Shc 
Figure 2:  Structure, tissue distribution, and ligand 
binding affinity of the IR-A and IR-B. Both receptors (IR-
A and IR-B) show high homology in their molecular 
structure ( L1, large domain 1; CR, cysteine-rich domain; 
L2, large domain 2; Fn, fibronectin type III domains; TM, 
transmembrane domain; JM, juxta membrane domain; TK, 
tyrosine kinase domain; CT, C-terminal domain; ID, insert 
domain). The hatched fragment on the bottom of the ID-α of 
IR-B (arrows) is encoded by exon 11 and is present in IR-B 
but not in IR-A. Below, the predominant tissue distribution 
of each receptor is shown. At the bottom of the figure, the 
different ligand binding affinity of each receptor is 
expressed as IC50 values (nM) of Insulin displacement 
(Frasca et al., 1999). 
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activation leads to the recruitment of Grb2 docking protein, which in turn recruits SOS with 
subsequent activation of the Ras→RAF→MEK→ERK1/2 signaling cascade that phosphorylates 
a plethora of cytosolic and nuclear proteins (SRC1, Pax6, STAT3, cFos, c-myc, and Elk1). Elk1 
kinase translocates to the nucleus and induces the transcription of several genes involved in cell 
proliferation and survival (Chang et al., 2003). 
 
1.3.2 Phosphatidylinositol 3- kinase (PI3K) – protein kinase B (AKT/PKB) cascade 
Insulin binding to the IR-B induces preferential activation of metabolic signals. This cascade 
starts with the phosphorylation of IRS1/2 and the activation of PI3K. 
Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases involved in the regulation of 
cell growth, metabolism, proliferation, glucose homeostasis and vesicle trafficking (Engelman et 
al., 2006). There are three classes in the family (Jean and Kiger, 2014): class I, II and III PI3K. 
All PI3Ks possess a ‘PI3K signature motif ’ that is composed of a C2 domain, which likely binds 
membranes, a helical domain and the catalytic kinase domain (Vanhaesebroeck and Alessi, 
2000). The classification of PI3Ks into the three different classes is based mainly on the presence 
of additional protein domains and their interactions with regulatory subunits. In vitro, all classes 
can generate phosphatidylinositol 3-phosphate (PtdIns(3)P), class I and II can synthesize 
phosphatidylinositol (3,4)-bisphosphate (PtdIns(3,4)P2), and only class I can produce 
phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) (Jean and Kiger, 2014) (Katso et al., 
2001). In vivo, there is significant support for class I PI3K synthesis of PtdIns(3,4,5)P3 and 
indirectly, PtdIns(3,4)P2, class III PI3K synthesis of PtdIns(3)P, and to a lesser extent, PI3K 
class II utilizes PtdIns(3)P to generate PtdIns(3,4)P2 and can also produce PtdIns(3)P from 
PtdIns (Jean and Kiger, 2014). Class I PI3K is further divided into IA and IB groups, activated 
by receptor tyrosine kinases (RTKs, PI3K1A) and G-protein-coupled receptors (GPCRs, 
PI3K1B). Class IA and IB PI3Ks have different regulatory subunits, p85a/p85b/p55 for IA and 
p101/p84/p87PIKAP for IB. Class II PI3K does not require a regulatory subunit to function, and 
comprises three different isoforms PI3K-C2α, PI3K-C2β, and PI3K-C2γ, (respectively encoded 
by PIK3C2A, PIK3C2B, and PIK3C2G genes), that diverge in the N terminus and present 
different domains within the C terminus. This class is involved in membrane trafficking and 
receptor internalization and can be activated in response to RTKs, integrins, and cytokine 
receptors (Engelman et al., 2006). Class III PI3K (Vps34), which was first identified in the 
budding yeast (Herman and Emr, 1990), is involved in vesicle trafficking and cross-talks with 
class I PI3K through the regulation of mTORC1 signaling (Backer, 2008).  Class I PI3K is the 
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most studied among the three members of the family, and I will refer to it as PI3K unless 
otherwise specified. 
IRS proteins via a specific phosphotyrosine (P) sequence, (pY)MXM and (pY)XXM motif, bind 
the heterodimer phosphatidylinositol 3- kinase (PI3K) at its two SH2 domains in the regulatory 
subunit. After dimerization of the different regulatory and catalytic subunits on IRS, PI3K 
catalyses the production of phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) from 
PtdIns(3,4) P2 at the plasma membrane. The lipid product of PI3Ks, PtdIns(3,4,5)P3, induces the 
activation of protein serine kinase cascades by co-recruitment to membranes of 
phosphoinositide-dependent kinase-1 (PDK1) and its substrate kinases AKT/PKB and atypical 
protein kinase Cs (aPKCs), via their respective PH domains (Mora et al., 2004).  
AKT propagates metabolic signals targeting substrates mostly involved in glucose and lipid 
homeostasis such as GLUT4, PDE3B, Foxa2, GSK3, and AMPK. Besides its role in metabolic 
effects, AKT leads to the activation of effectors involved in the control of apoptosis and survival 
(BAD, Mdm2, FKHR, NFkB and JNK) and protein synthesis and cell growth (mTOR). 
 
 
Figure 3: Schematic representation of IR signaling. Ligand binding to the α-subunit of IR stimulates the tyrosine kinase 
activity intrinsic to the β-subunit of the receptor, which in turn phosphorylates several substrates including IRS1/2 and 
Shc/Grb2/Sos complexes. IRS proteins interact with the regulatory subunit of PI3K leading to the activation of AKT. 
Phosphorylated IRS1/2 are also able to recruit the Grb2/Sos complex, which triggers the RAS/RAF/MEK/ERK pathway 
(Belfiore and Malaguarnera, 2011).  
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1.4 Cross-talk between PI3K and MAPK pathways 
Importantly, the two main pathways regulated by insulin receptor are not totally independent, as 
they can regulate each other. Indeed, PI3K pathway impacts on Ras–MAPK at multiple levels. 
Ras activation by PI3K has been well characterized in lysophosphatidic acid (LPA)-induced 
MAPK activation, where PI3K pharmacological inhibitors blunt the activation of ERK kinase. 
This activation partially relies on G-beta gamma subunits and Shc-Grb2-Sos activation as well as 
in PtdIns (3,4,5)P3-mediated PKCz activation. Nevertheless, the specific requirement of PI3K 
for Ras activation might be tissue-specific and involve additional signaling molecules (Yart et 
al., 2002). Similarly, somatostatin receptor (Lahlou et al., 2003), as well as insulin and low doses 
of EGF (Wennström and Downward, 1999), can drive Ras activation through PI3K, which may 
be due to the ability of PtdIns(3,4,5)P3 to recruit GAP/Shp2 in some circumstances (Sampaio et 
al., 2008). On the other hand, some PI3K inhibitors such as the cytokine b-galactosidase-binding 
protein (bGBP) inhibit MAPK (Wells et al., 2007). The cellular context in which PI3K signals to 
Ras is not yet elucidated, and further research on the role of PI3K-Ras binding, PtdIns species 
production and involvement of the different PI3K isoforms is required for the proper delineation 
of this signaling cross-talk. Morevoer, PI3K pathway can directly modulate the Ras target Raf 
therefore bypassing the GTPase. AKT phosphorylates c-Raf in Ser259 (Zimmermann and 
Moelling, 2016) and B-Raf (Nadimpalli et al., 2000). This inhibitory phosphorylation on Raf 
reduces the activity of MAPK pathway (Zimmermann and Moelling, 2016). This action of AKT 
on MAPK pathway is crucial for proper regulation of differentiation in some tissues and for cell 
survival (Rommel et al., 1999) and may  impact on the response to growth factors (Nadimpalli et 
al., 2000). Another protein kinase with similar catalytic domain to AKT, SGK has also been 
suggested to phosphorylate Raf in an AKT site (Zhang et al., 2001). In which circumstances 
AKT inhibits Raf is still unclear; and the strength of PI3K activation may regulate this cross-talk, 
as AKT phosphorylation of Raf is more prominent at higher PI3K activity (Moelling et al., 
2002).  
  
The expression of a mutant dominant-negative form of p85 (Rodriguez-Viciana et al., 1997) or 
mutation of PI3K-IA (Gupta et al., 2007) reduces Ras-mediated transformation and the 
aggressiveness of lung tumors in Ras mutant transgenic mice. On the other hand, Ras influeces 
PI3K regulation. Indeed, class I and II PI3K isoforms have a Ras Binding Domain (RBD) by 
which Ras facilitates PI3K anchorage to the membrane and thus its full activation (Engelman et 
al., 2006). Ras binding to PI3K is required to transmit EGF and FGF2 extracellular signals, 
which accounts for a primary role of Ras in the regulation of PI3K signal transduction (Ramjaun 
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and Downward, 2007). Moreover, the oncogenic ability of Ras is linked to its ability to activate 
this pathway (Rodriguez-Viciana et al., 1997)(Gupta et al., 2007). 
With regards to the interaction between Ras and PI3K, it has been demonstrated to be critical for 
correct cell polarity and migration. Studies carried out in Dictyostelium and hippocampal 
neurons show that the proper cross-talk of these two pathways is essential for axon formation 
and cell polarity and migration (Funamoto et al., 2002)(Sasaki et al., 2007)(Fivaz et al., 2008). 
Moreover, in Dictyostelium, cytoskeleton components such as F-actin filaments play an 
important role in the signaling between PI3K and Ras, promoting their correct localization and 
interaction in the plasma membrane (Sasaki et al., 2007). Therefore, the PI3K pathway plays a 
critical role in cell polarity, chemotaxis and migration, which requires a tightly regulated cross-
talk with Ras pathway. The biological consequences of MAPK and PI3K cross-talk are being 
actively investigated as they may selectively impact in some cellular responses but not others. 
 
2. AKT KINASES: THREE DIFFERENT TEAM PLAYERS IN CANCER? 
 
2.1 Protein kinase B (PKB)/ AKT 
Protein kinase B (PKB, also termed Akt or RAC ) is a 57 kDa serine/threonine kinase belonging 
to the “AGC “ (related to AMP/GMP kinase and protein kinase C) superfamily of protein kinases 
(of which there are over 80 members) that includes PKA, PKC, PDK1, and the p70 and p90 S6 
kinases (Coffer and Woodgett, 1991). This group of kinases shares similarity within their 
catalytic domain structure and in their mechanism of activation, and many are frequently 
deregulated in human diseases including cancer. The catalytic domain of AKT is structurally 
similar to that of other protein kinases of the AGC family including PKA (Yang et al., 2002). 
Mammals have three closely related AKT genes, encoding the isoforms AKT1 (PKBα/RAC-
PKα), AKT2 (PKBβ) and AKT3 (PKBγ).  
AKT1 and AKT2 are ubiquitously expressed, although at varying levels, while AKT3 is 
restricted to some tissues (Masure et al., 1999). Specifically, AKT3 is highly expressed in brain 
and testis, with low levels in pancreas, skeletal muscle, and kidney (Nakatani et al., 1999). 
AKT2 and AKT3 show 81 and 83% amino acid identity with AKT1 respectively.  
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Figure 4: Domain structure of the AKT family members and homology models of the ATP binding regions. All AKT 
family members contain an N-terminal pleckstrin homology domain, a catalytic kinase domain, and a C-terminal regulatory 
hydrophobic region. Computer-derived homology models of the ATP binding regions of the three AKTs are shown. ATP binding 
site is shown in blue. Residues unique to the AKT family members are colored in magenta and labeled. Staurosporine is in 
yellow (Bellacosa et al., 2005). 
 
All AKT isoforms consist of an N- terminal PH domain, a kinase domain and a C-terminal 
regulatory tail (Vahaesbroneck and Alessi, 2000). The N-terminal PH domain is common to 
numerous signaling proteins and provides a lipid binding module to direct AKT to PI3K-
generated phosphoinositides PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (Manning and Cantley, 2007). 
The second important domain of AKT is the C-terminal HM domain presents in many other 
AGC kinases (Vahaesbroneck and Alessi, 2000) (Pearson et al., 1995). Studies on AKT and 
other AGC kinases including protein kinase C, p70 ribosomal S6 kinase, serum and 
glucocorticoid-activated kinase (SGK) and RSK indicate that the HM provides a role in 
regulating kinase activity. Indeed, the HM domain provides a docking site for the upstream 
activating kinase,  such as phosphoinositide-dependent kinase-1 (PDK1) (Balendran et al., 2000). 
Two specific sites, one in the kinase domain (Thr 308 in AKT1, Thr 309 in AKT2, Thr 305 in 
AKT3) and other in the C-terminal regulatory region ( Ser 473 in AKT1, Ser 474 in AKT2, Ser 
472 in AKT3 ), need to be phosphorylated for full activation of these kinases. These 
phosphorylations are performed by the serine/threonine kinases PDK1 and PDK2 or mTORC2 
respectively (Alessi et al., 1997) (Jacinto et al., 2006). PDK1 activates AKT/PKB and PKCα by 
phosphorylation of serine/threonine residues in their kinase regulatory loops (Pearce et al., 
2010). Activation of AKT/PKB additionally requires phosphorylation of a C-terminal 
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hydrophobic motif, catalysed by a distinct enzyme, most probably mTORC2 or DNA-PK 
(Bozulic and Hemmings, 2009). Indeed, Rictor-mTOR complex can also phosphorylate AKT1 
on S473, facilitating T308 phophorylation by PDK1 (Sarbassov, 2005). 
 
As with other AGC kinases, AKT is regulated by upstream, second messengers and secondary, 
activating enzymes. For AKT, this activating process involves multiple inputs that strictly 
control the location, duration and strength of response (Balendran et al., 2000).  
The duration and amplitude of AKT signalling are controlled by PP2A and PHLPP phosphatases 
that specifically dephosphorylate AKT on the hydrophobic phosphorylation motif (Brognard et 
al., 2007). Indeed, several reports have indicated that AKT can be activated in cells by a 
mechanism independent of PI3K activation, for example in response to heat shock, or increases 
in intracellular Ca5+ or cAMP (Moule et al., 1997)(Filippa et al., 1999).  
 
 
 
 
 
 
Activated AKT/PKB phosphorylates multiple substrates, the majority characterized by the 
RXRXX consensus sequence (S / T) (Fayard, 2005), and controls a variety of downstream 
responses depending on cell type (Manning and Cantley, 2007). In some cases, phosphorylation 
of targets itself regulates activity, while in other cases binding of 14-3-3 protein also plays a role 
(Johnson et al., 2010). Well-established AKT/PKB substrates include GSK-3, regulating 
glycogen synthesis; the Rab GTPase activating protein AS160/TBC1D4, regulating glucose 
Figure 5: Schematic depicting the conformational 
changes accompanying AKT activation and the role 
of the phosphorylated hydrophobic motif in the 
activation cycle. (A) AKT in its unphosphorylated 
state remains cytosolic and is inactive. In 
unphosphorylated AKT, the activation (or T-loop), αB, 
and αC helices and the hydrophobic motif (HM) 
remain disordered. PDK2 phosphorylates AKT on Ser  
in the HM. (B) PI3K-generated PtdIns(3,4,5)P3 and 
PtdIns(3,4)P2 recruit AKT and PDK1 to the plasma 
membrane. Phosphorylated HM stabilizes and 
activates PDK1, which then phosphorylates AKT on 
Thr. (C) The HM of AKT associates with and 
stabilizes the kinase domain, leading to ordered 
structures for αB and αC helices and the activation (T-
loop). PH indicates the plekstrin homology domain; 
red circles denote phosphate groups (Bellacosa et al., 
2005).  
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transport; the Rheb GTPase activating complex TSC1/2, regulating mTOR and protein synthesis; 
FOXO transcription factors, regulating expression of gluconeogenic and other genes; BAD and 
Mdm2, regulating apoptosis (Manning and Cantley, 2007). Both AKT-dependent and -
independent mechanisms have been implicated in regulation of adipose tissue lipolysis by insulin 
(Choi et al., 2010).  
New AKT substrates continue to be validated in vivo; it is currently less clear, however, to what 
extent AKT1, AKT2, and AKT3 are functionally redundant, or each kinase carries out a specific 
functional role (Bellacosa et al., 2004). 
Since the AKT signaling cascade is frequently disrupted in many human cancers, and in light of 
the wide-ranging biologic consequences, this pathway is considered a key determinant of tumor 
aggressiveness and an attractive target for therapeutic intervention. 
 
2.2 “AKTivation” in cancer 
The three AKT kinases are now known to represent central nodes in a variety of signaling 
cascades that regulate normal cellular process such as cell size/growth, proliferation, survival, 
glucose metabolism, genome stability, and neo-vascularization (Bellacosa et al., 2004)(Dummler 
and Hemmings, 2007) (Vara et al., 2004). 
A large body of literature has documented frequent hyperactivation of AKT kinases in a wide 
assortment of human malignancies (Bellacosa and Kumar, 2005), and a series of elegant studies 
using animal models has demonstrated that aberrant AKT signaling can, either alone or by 
cooperating with certain other genetic perturbations, induce malignancy or contribute to a more 
malignant phenotype (Bellacosa et al., 2004)(Bjornsti and Houghton, 2004). Many human 
cancers, including carcinomas, glioblastoma multiforme, and various hematological 
malignancies, exhibit AKTs hyperactivation (Altomare and Testa, 2005). AKT1 is often 
hyperactivated in prostate, breast, ovarian cancers and in gastric adenocarcinomas (Staal, 1987) 
with the exception of kidney, liver, and spleen (Altomare et al., 1998). Amplification of AKT2 
has been detected in ovarian cancer, breast cancer, pancreatic cancer, non-Hodgkin’s lymphoma, 
and hepatocellular carcinoma (Bellacosa and Kumar, 2005)(Cheng et al., 1992)(Cheng et al., 
1996)(Xu et al., 2004). Increased AKT3 protein levels and activity were detected in estrogen 
receptor deficient breast cancer cells and androgen-independent prostate cancer cells (Nakatani 
et al., 1999). 
Numerous investigators have reported correlations between tumor, AKT activity and various 
clinicopathologic parameters (Bellacosa and Kumar, 2005). Moreover, Joy’s group show that 
AKT3 mRNA is inversely associated with grade and survival in GBM, AKT3 mRNA is elevated 
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in the less aggressive subtype of GBM and AKT3 overexpression increases survival in an 
orthotopic rodent xenograft model of GBM, decreasing colony forming efficiency in glioma 
cells. In addicition silencing of AKT3 slows cell cycle progression and increases apoptosis (Joy 
et al., 2016).  In particular, AKT activation has been shown to correlate with advanced disease 
and/or poor prognosis in some tumor types.  
AKT pathway is a central node in a signaling pathway consisting of many components that have 
been implicated in tumorigenesis, including upstream phosphatidylinositol 3-kinase (PI3K), 
PTEN (Phosphatase and Tensin homologue deleted on chromosome Ten), NF1 and LKB1, and 
downstream tuberous sclerosis complex 2 (TSC2), Forkhead Box Class O (FOXO) and 
eukaryotic initiation factor 4E (eIF4E). Several of these proteins (AKT, eIF4E, and both the 
p110α catalytic and p85α regulatory subunits of PI3K) can behave as oncoproteins when 
activated or overexpressed, while others (PTEN, FOXO, LKB1, TSC2/TSC1, NF1, and VHL) 
are tumor suppressors. Somatic genetic and/or epigenetic changes involving genes encoding 
these AKT pathway components are among the most frequent alterations reported in sporadic 
cancers.  
Indeed, perturbation of the upstream PTEN and PI3K contributes to activation of the AKT 
pathway in human tumors (Simpson and Parsons, 2001). Moreover, other mechanism such as 
activation of PI3K due to autocrine or paracrine stimulation of receptor tyrosine kinases (Yuan et 
al., 2000)(Tanno et al., 2001)(Sun and Steinberg, 2002), overexpression of growth factor 
receptors such as the epidermal growth factor receptor in glioblastoma multiforme (Schlegel et 
al., 2002) and HER-2/neu in breast cancer (Bacus et al., 2002), and/or Ras activation (Liu et al., 
1998) promotes AKT activation. In some instances, AKT activation may result from 
overexpression of a wild-type growth factor receptor. In such cases, the abundance of a given 
receptor may enable a tumor cell to become hypersensitive to ambient levels of growth factors 
(Hanahan and Weinberg, 2000). Mutant receptors, on the other hand, can give rise to constitutive 
activation of the AKT signal transduction pathway (Sordella et al., 2004). Furthermore, in certain 
hematological malignancies, constitutive activation of AKT can result from a chromosomal 
translocation that triggers permanent activation of an upstream tyrosine kinase (Slupianek et al., 
2001). 
Although AKT kinases are often hyperactivated throught different mechanisms, mutation of this 
kinases is a rare event in cancer. A somatic mutation in human breast, colorectal and ovarian 
cancers that results in a glutamic acid to lysine substitution at amino acid 17 (E17K) in the lipid-
binding pocket of AKT1 has been identified. Lysine 17 alters the electrostatic interactions of the 
pocket and forms new hydrogen bonds with a phosphoinositide ligand. This mutation activates 
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AKT1 by means of pathological localization to the plasma membrane, stimulates downstream 
signalling, transforms cells and induces leukaemia in mice (Carpten et al., 2007). The single 
hotspot mutation G49A:E17K occurs most often in AKT1, but the corresponding E17K mutation 
has also been found in AKT2 and AKT3 (Yi and Lauring, 2016). This mechanism indicates a 
direct role of AKTs in human cancer, and adds to the known genetic alterations that promote 
oncogenesis through the PI3K/AKT pathway. 
AKTs play a relevant role in many cellular processes that, when deregulated, can contribute to 
the development or progression of cancer. Activated AKT is a well-established survival factor, 
exerting antiapoptotic activity, in part by preventing the release of cytochrome c from the 
mitochondria (Zhou et al., 2000). AKT also phosphorylates and inactivates the proapoptotic 
factors BAD and procaspase-9 (Datta et al., 1999)(Downward, 1998). Moreover, AKT-
dependent phosphorylation and inactivativation of the FOXO transcription factors, inhibits the 
expression of genes critical for apoptosis, such as the Fas ligand gene (Brunet et al., 
1999)(Zhang et al., 2011)(Hay, 2011). Moreover, nuclear AKT2 selectively inhibits FOXO 
inhibition and its downregulation results in a gain of FOXO functions. AKT2 nuclear signaling 
opposes lymbal keratinocyte stem cells (LKSCs) maintenance by selective regulation of a 
FOXO-mTORC1 signaling pathway In addiction, in limbal karatinocyte stem cell population 
individual Akt isoforms play opposite roles where AKT1 promotes while AKT2 opposes LKSC 
self-renewal (Saoncella et al., 2004).  
AKT also activates IkB kinase (IKK), a positive regulator of NF-kB, which results in the 
transcription of antiapoptotic genes (Pommier et al., 2004). In another mechanism to thwart 
apoptosis, AKT promotes the phosphorylation and translocation of Mdm2 into the nucleus, 
where it downregulates p53 and thereby antagonizes p53-mediated cell cycle checkpoints (Mayo 
and Donner, 2002)(Zhou et al., 2001). VEGF effects on cell survival have also been shown to be 
mediated by the Flk1/VEGFR2-PI3K-AKT pathway (Shiojima and Walsh, 2002). 
AKT activation stimulates cell cycle progression by phosphorylation and consequent inhibition 
of glycogen synthase kinase 3β to avert cyclin D1 degradation (Liang and Slingerland, 2003). 
AKT also directly antagonizes the action of the cell cycle inhibitors p21WAF1 and p27Kip1 by 
phosphorylating a site located near the nuclear localization signal to induce cytoplasmic 
retention of these cell cycle inhibitors (Testa and Bellacosa, 2001)(Bellacosa and Kumar, 2005). 
Moreover, AKT-induced phosphorylation of mTOR kinases also results in increased translation 
of cyclin D1, D3, and E transcripts (Muise-Helmericks et al., 1998). AKT activates the 
downstream mTOR kinase by inhibiting a complex formed by the tumor suppressor proteins 
TSC1 and TSC2, also known as hamartin and tuberin (Astrinidis and Henske, 2005).  
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mTOR broadly mediates cell growth and proliferation by regulating ribosomal biogenesis and 
protein translation (Ruggero and Sonenberg, 2005) and can regulate response to nutrients by 
restricting cell cycle progression in the presence of suboptimal growth conditions (Plas and 
Thompson, 2005). Finally, AKT has also been shown to phosphorylate human telomerase 
reverse transcriptase, which stimulates telomerase activity and replication (Liu, 1999). 
Tumor cell migration is also linked to AKT signaling (Lefranc et al., 2005). AKT has been 
shown to contribute to tumor invasion and metastasis by promoting the secretion of matrix 
metalloproteinases (Thant et al., 2000), the induction of epithelial-mesenchymal transition 
(EMT) and by sustaining the remodelling of actin filaments via Girdin (an ubiquititous acting-
binding protein) phosphorylation (Enomoto et al., 2006) (Larue and Bellacosa, 2005). In human 
lung cancer cell Non-Small Cell Lung Cancer cells LNM3, depletion of AKT1 decreases cellular 
invasion at least in part via COX-2 inhibition, with no effect on cell motility, proliferation, 
colony formation, and angiogenesis (Attoub et al., 2015). Unexpectedly, AKT1 can also decrease 
breast cancer cell migration through phosphorylation and activation of the E3 ubiquitin ligase 
Mdm2, promoting ubiquitination and proteosomal degradation of NFAT transcription factor 
(Yoeli-Lerner et al., 2005). Activation of AKT2 in ovarian and breast cancers under nutrient-
poor conditions results in migration, with increased attachment and invasion through collagen IV 
(Arboleda et al., 2003)(Chau and Ashcroft, 2004). Moreover, silencing of Akt2 also reduced 
cellular motility and invasion in vitro, presumably via COX-2 inhibition (St-Germain et al., 
2004). In addition, AKT2 is necessary for migration of glioma cell lines (Zhang et al., 2010). 
Interestingly, AKT3 is required for the migration of transformed astroytes (Endersby and Baker, 
2008), but can inhibit cell migration and metastasis formation in triple negative breast cancer 
(Grottke et al., 2016). 
AKT signaling also contributes to other cellular processes considered to be cancer hallmarks 
(Hanahan and Weinberg, 2000), further confirming the key role of AKT pathway upregulation in 
many aspects of tumorigenesis. 
 
3. MUTANT P53 AND ITS GAIN OF FUNCTION (GOF) IN CANCER 
 
3.1 p53: from tumor suppressor to oncogene 
Wild type p53 (wt) is a sequence specific transcription factor (Laptenko and Prives, 2006) with a 
relevant tumor suppressive role that makes it the “guardian of the genome” and one of the most 
important players in cancer biology (Freed-pastor and Prives, 2012). In normal cells, p53 can be 
activated by numerous cellular stressors, including DNA damage, oncogenes activation and 
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hypoxia, and its low levels rise dramatically, resulting in the transcription of many genes with 
important roles in cell cycle arrest, senescence, apoptosis, DNA repair, metabolism, autophagy 
and differentiation (Meek, 2009). Tumors arise upon loss of p53 function through various 
mechanisms, including deletion or mutation of the p53 gene itself, overproduction of the p53 
inhibitors, Mdm2 and Mdm4, or viral inactivation (Vogelstein et al., 2000)(Wasylishen and 
Lozano, 2017). Not surprisingly, the TP53 gene is the most frequent target for mutation in 
human cancer: 96% in ovarian serous carcinoma, 54% in invasive breast carcinoma, and 75% in 
pancreas cancer (Kim et al., 2014). Loss of p53 function is often a prerequisite for tumor 
initiation and progression, which has been most clearly demonstrated by the increased cancer 
risk in Li–Fraumeni syndrome patients (LFS) with germline p53 mutations and p53 knockout 
mouse models (Lang et al., 2004)(Donehower et al., 1992).  Frameshift or nonsense mutations 
result in the loss of p53 protein expression, as seen with other tumor suppressors (Kim et al., 
2014). Regardless of the mechanism of p53 inactivation, loss of tumor suppressive activities 
exerted by p53 may result in unrestricted cell proliferation and the permissive accumulation of 
genomic infractions that culminate in tumor growth. Moreover, among cancers with TP53 
mutations, ~ 60% show concomitant deletion of the other allele, termed loss of heterozygosity 
(LOH). In cancer cells that do not undergo LOH of the wild-type TP53 allele, a dominant 
negative mechanism may inhibit wild-type p53 (Muller and Vousden, 2014). Moreover, the loss 
of normal p53 function is likely coupled with the adoption of new biologic functions exerted by 
mutant p53 proteins with additional, deleterious effects.  
 
 
 
 
Figure 6:  Mutant p53 
functions during the 
evolution of a cancer cell. 
The picture represents the 
general evolution of a normal 
cell into a transformed cell 
(carcinoma), and the contexts 
in which mutant p53 exerts 
its functions (Sabapaty 
2015).  
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In contrast to other tumor suppressors, that are commonly inactivated by frameshift and 
nonsense mutations leading to production of truncated proteins or complete elimination of the 
corresponding gene products, the majority of p53 alterations are missense mutations, leading to 
the substitution of a single amino acid in the p53 protein (Kim et al., 2014)(Muller and Vousden, 
2014), resulting in the expression of full-length mutant p53 (mutp53) proteins (Hussain and 
Harris, 1998).  
The full-legnth mutated p53 proteins become highly expressed in human cancers due to its 
prolonged half-life, reaching levels far above those observed in normal cells expressing wild-
type p53 (wtp53) (Freed-pastor and Prives, 2012)(Strano et al., 2007).  
Single aminoacid substitutions have been detected throughout the p53 protein, but the great 
majority clusters within the central DNA binding domain (in about 90% of cases) (Kim et al., 
2014). Six “hotspot” residues are the most frequently substituted, including amino acid residues 
R175, G245, R248, R249, R273, and R282. 
Mutations of p53 can affect its transcriptional activity or can also have significant consequences 
to the folding of p53 and to the capability to establish new interactions. Therefore, they are 
broadly categorized as those that alter the structure of the binding domain, defined as 
“conformational mutant” (e.g. R175, G245, and R249), or those that diminish the ability of 
mutant p53 to bind DNA, known as “contact mutant” (e.g. R248, R273 and R282) (Muller and 
Vousden, 2014). Conformational mutations usually result in a more dramatic alteration of p53 
protein structure compared with DNA contact mutants. 
More important, the changes in p53 structural stability may be crucial to the acquisition of new 
oncogenic properties (Muller and Vousden, 2014). Indeed, numerous mouse models, in vitro and 
clinical studies have demonstrated that in addition to simple loss of the tumor suppressor 
function of p53, many mutant p53 (mutp53) proteins gain neomorphic oncogenic activities, 
termed as gain-of-function (GOF) (Dittmer et al., 1993). Indeed, several studies have found that 
the median age of cancer onset in Li-Fraumeni Syndrome patients with mutp53 missense 
mutations is 9–20 years earlier than in LFS patients with loss of p53 expression (Zerdoumi et al., 
2013)(Bougeard et al., 2008). Functionally, mutant p53 GOF activities contribute to malignant 
transformation by enhancing cells proliferation, invasion, metastatic ability, and chemoresistance 
(Muller and Vousden, 2014). 
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3.2 Mechanisms of mutant p53 gain of function  
The vast majority of missense mutations in TP53, as described above, occurs at hotspots located 
within the DNA-binding domain. Ineffective binding of p53 to consensus DNA sequences in 
target gene promoters attenuates tumor suppressive mechanisms and reduces barriers to cell 
proliferation. Although mutant p53s have generally lost the ability to bind consensus p53 DNA 
binding regions in target gene promoters, their activity appears to reflect an ability to regulate 
gene expression directly (Weisz et al., 2007). Various different mutant p53s can bind directly to 
DNA with some degree of selectivity (Brázdová et al., 2013)(Göhler et al., 2005); and may 
thereby directly control the transcription of some genes (Weisz et al., 2007). Nevertheless, a 
consensus for mutant p53-specific binding has so far not been identified (Muller and Vousden, 
2014). Moreover, cytoplasmic and mitochondrial activities of mutant p53 in regulating apoptosis 
and autophagy have also been described (Chee et al., 2013)(Frank et al., 2011)(Morselli et al., 
2008). Indeed, the relative inability of mutant p53 to directly bind DNA suggests that the mutant 
p53 GOF is the product of functional partnerships between mutant p53 proteins and available 
interacting proteins that together mediate changes in cell phenotypes through altered gene 
expression. Importantly, numerous studies have demonstrated an intact p53 transactivation 
domain as requisite for specific mutant p53 GOF activities, again indicating codependence on 
other transcriptional regulators for exertion of GOF (Bullock and Fersht, 2001)(Vousden and 
Prives, 2009). GOF properties were better studied with the generation of the p53 mutant knock-
in mice (Caulin et al., 2007)(Morton et al., 2010). Moreover, the spectrum and extent of GOF 
Figure 7: TP53 mutational 
spectrum in human cancer. 
Schematic representation of the p53 
protein with domains structure 
illustrated: TAD: transactivation 
domain; PRD: proline-rich-domain; 
DBD: DNA-binding domain; OD: 
oligomerization domain (also 
contains a nuclear export signal); 
CTD: C-terminal regulatory domain 
(also contains three nuclear 
localization signals). The six 
hotspot mutations are highlighted 
(Freed-Pastor and Prives, 2012). 
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activities endowed by p53 missense mutations change with mutation type. Knock-in p53 alleles 
with point mutations at codons R172H and R270H (equivalent to R175 and R273 in humans, 
respectively) showed different tumor spectra: mice heterozygous for the p53R270H mutation 
have a higher incidence of carcinomas and B-cell lymphomas compared with mice with one null 
p53 allele (Vogelstein et al., 2000). Similarly, p53R172H mutant mice develop more 
osteosarcomas with higher rates of metastasis than the R270H mutant (Vogelstein et al., 2000). 
Humanized p53 knock-in (HUPKI) mice express human coding sequences of the p53 DNA-
binding domain and hotspot mutations at codons R248Q and G245S (Toledo et al., 2006).  
Homozygous p53R248Q mutant mice demonstrated a shortened overall survival owing to 
accelerated time-to-tumor formation (TTF) relative to p53-null mice. However, homozygous 
p53G245S mice had similar overall survival and tumor spectrum to p53-null mice, indicating 
altered GOF activities of mutant p53 proteins with R248Q versus G245S mutations. In addition, 
mice with mutant p53R248Q showed increased early expansion of the hematopoietic and 
mesenchymal stem cell pools relative to mutant p53G245S and p53-null mice. Based on the site 
and nature of missense mutations – conformation versus structural – mutant p53 proteins likely 
possess different conformations that affect the spectrum of interacting proteins. Indeed, mutant 
p53 proteins acquire a plethora of gain-of-function (GOF) effects that depend on its ability to 
bind other proteins and alter gene expression, and all of these mechanisms provide advantage to 
the cancer cell.  
 
 
Figure 8: Molecules that are 
associated with mtp53 GOF. Mutant 
p53 GOF contributes to cancer 
through direct interaction with 
proteins altering their activity or 
through transcriptional activation or 
repression of target genes and 
downstream molecules (Ashauer and 
Muller 2016). 
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3.2.1 Interactions mediating mutant p53 transcriptional activities 
Mutant p53 gain of function includes both transcriptional and non-transcriptional mechanisms. 
Regarding transcriptional activities, mutp53 can bind transcription factors (TFs) to transactivate 
target genes or attenuate target gene expression. In addition, mutp53 may also function to 
increase chromatin accessibility and drive the expression of genes contained within distinct 
regions of the genome. The partnership with transcription factors has been recognized as a 
central mechanism through which the impact of mutant p53 GOF is mediated and amplified. In 
fact, mutant p53 interacts with transcription factors and cofactors to control gene expression. 
Interactions of mutant p53 with different TFs, such as NF-Y, p63, p73, YAP, SREBP; ETS2, 
VDR, Sp1 and NRF2 (Hamroun et al., 2006)(Xu et al., 2011) (Di Agostino et al., 2006) (Di 
Agostino et al., 2015)(Haupt et al., 2016)(Do et al., 2012)(Stambolsky et al., 2010)(Chicas et al., 
2000)(Tung et al., 2015), have been demonstrated to sustain cancer progression. 
Different GOF mutant p53 proteins (p53R280K, p53R175H, p53A193T, p53R248L, p53R273H, 
p53L194F, and p53P309S), but not wild-type p53 protein, can physically interact with YAP. The 
protein complex YAP/mutant p53 can form with the transcription factor NF-Y a large multi-
protein complex that is recruited onto the regulatory regions of its target genes (Di Agostino et 
al., 2015). In addition mutant p53 directly interacts with NF-Y to recruit p300 acetyltransferase 
on the promoters of NF-Y target genes (CCNA, CCNB1, CDK1, and CDC25C) resulting in 
increased cell proliferation (Di Agostino et al., 2006). Mutant p53 proteins also bind p63 and p73 
to repress activation of their respective target genes, leading to increased cell motility, invasion, 
and metastasis (Li and Prives, 2007). Mutant p53R175H and R273H bind to p73 and prevent its 
binding to NF-Y on the PDGFRβ promoter, allowing PDGFRβ expression (Blandino et al., 
1999). By inhibiting TAp63, mutant p53 can regulate a pro-invasive transcription program that 
includes regulation of the expression of Dicer, DEPDC1, Cyclin G2, and Sharp1 (Muller et al., 
2014)(Adorno et al., 2009) (Girardini et al., 2011). Moreover, in a more recent study it has 
become apparent that mutant p53 can bind to different Smad proteins, both promoting and 
inhibiting TGFβ signalling (Ji et al., 2015).  
Additionally, mutant p53 proteins can up-regulate genes that inhibit apoptosis or promote 
chemoresistance. For example, mutant p53 promotes NF-κB transcription and activation, 
inducing a pro-survival signalling (Weisz et al., 2007). Vadlamudi’s group also demonstrated 
that Proline-, Glutamic acid-, and Leucine-rich Protein-1 (PELP1) PELP1 plays an important 
role in the modulation of mutant p53 anti-apoptotic functions. Indeed, PELP1 interacts with 
mutant p53, regulates its recruitment on DNA, and alters epigenetic marks at target gene 
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promoters. This interaction could influence mutant p53 oncogenic functions with potential 
implications in chemotherapy response, and overall prognosis of patients (Krishnan et al., 2015). 
Finally, mutant p53 has been demonstrated to transactivate multiple genes involved in cancer 
cell proliferation and survival. For istance mutant p53 can transactivate CXCL1 (Yan and Chen, 
2009), PCNA (Deb et al., 1992), MYC (Frazier et al., 1998), MAP2K3 (Bossi et al., 2008), 
ASNS (Scian et al., 2004), E2F5, MCM6 (Scian, 2005), STMN1 (Singer et al., 2007), IGF1R 
(Werner et al., 1996), and EGFR (Ludes-Meyers et al., 1996), all of which can promote 
proliferation of cancer cells. Additionally, mutant p53 proteins can transactivate EGR1(Weisz et 
al., 2004), ABCB1 (also known as MDR1 or P-glycoprotein) (Sampath et al., 2001), IGF2 (Lee 
et al., 2000), DUT (Pugacheva et al., 2002), BCL2L1 (also known as Bcl-xL) (Bossi et al., 
2008), TIMM50 ( Sankala et al., 2001), and LGALS3 ( Lavra et al., 2009) all of which can 
inhibit cell death. 
Conceptually, a single mutant p53 variant may interact with multiple TFs, and TFs complexed 
with mutant p53 may transactivate genes normally regulated by such TFs, therefore the number 
of genes potentially affected by mutant p53 can be very large. 
 
3.2.2 Interactions mediating mutant p53 transcription-independent activities 
Mutant p53 can form complexes with many proteins that are not involved in transcription, and 
this also contributes to its gain-of-function. Song et al. identified interactions between mutant 
p53 and Mre11 that result in impaired Ataxia-telaniectasia mutated activation, resulting in the 
disruption of DNA damage response elements and genetic instability (Song and Xu, 2007). 
Moreover, mutant p53 was also reported to interact with topoisomerase 1, which maintains DNA 
topology, resulting in hyperrecombination and genomic instability (Restle et al., 2008). Prolyl 
isomerase Pin1, which regulates conformational changes of proteins to affect protein stability 
and activity, was reported to be an additional mutant p53-binding protein. In breast cancer cells, 
Pin1 enhances the oncogenic activity of mutant p53 to promote aggressiveness through mutant 
p53-dependent inhibition of p63 and induction of a mutant p53 transcriptional program 
(Girardini et al., 2011).  
 
3.3 Cytoplasmic interactions of mutant p53 
In addition to nuclear functions, mutant p53 has cytoplasmic functions that contribute to its 
GOF. The stability of mutant p53 proteins facilitates their accumulation in the cytosol, and 
mutant p53 is easily detected in purified cytoplasmic fractions in various cancer cell lines 
(Di Minin et al., 2014)(Morselli et al., 2008)(Green and Kroemer, 2009). Thus, mutant p53 has 
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the opportunity to form aberrant complexes with cytoplasmic proteins, potentially altering their 
functions. 
For istance, under condition of energy stress, mutant p53, but not wild-type p53, directly binds to 
the AMP-activated protein kinase alpha (AMPKα) subunit via the DBD, while its N terminus 
blocks AMPKα-LKB1(liver kinase β 1) interaction, thus leading to inhibition of AMPK activity. 
AMPK is the major cellular energy sensor and a master regulator of metabolic homeostasis. GOF 
mutant p53s negatively regulates the metabolic effects of AMPK signaling, leading to increased 
lipid production, aerobic glycolysis, and invasive cell growth in head and neck cancer cell lines 
(Zhou and Myers, 2014).   
We have found that mutant p53 binds DAB2IP in the cytoplasm, interfering with its 
physiological interactions. DAB2IP is a cytoplasmic Ras-GTPase activating protein that also 
functions as a signaling scaffold to modulate the cell's response to multiple oncogenic 
extracellular signals, including TNFα (Di Minin et al., 2014) and Insulin (Valentino et al., 
2017a) (this thesis). The interaction between mutant p53 and DAB2IP is the main focus of this 
Thesis and it will be discussed in more detail in a following chapter. 
Finally, Yue and collegues recently demonstrated that mutant p53 binds members of the 
monomeric GTPase family of proteins (Yue et al., 2017). Specifically, mutant p53 interactes 
with and activates Rac1. Rac1 is a small GTPase that regulates many cellular functions, 
including cell proliferation, cytoskeletal reorganization, and cell mobility. As all GTPases, Rac1 
cycles between the inactive GDP-bound (Rac1-GDP) and the active GTP-bound (Rac1- GTP) 
forms (Bid et al., 2013)(Heasman and Ridley, 2008). Rac1 SUMOylation is critical to maintain 
the active GTP-bound form, and thus its activity. The sumo-specific protease SENP1 de-
SUMOylates Rac1, leading to its inactivation (Castillo-Lluva et al., 2010).  Mechanistically, 
mutant p53 inhibits the interaction of SENP1 with Rac1 and its de-SUMOylation, thereby 
activating Rac1, in turn promoting tumor growth and metastasis (Yue et al., 2017). 
 
3.4 Mutant p53 modulates multiple pathways in cancer 
Mutant p53 activities interact with multiple pathways involved for cancer progression. Indeed, 
mutant p53 has been shown to inhibit BTG2 anti-proliferative protein promoting H-Ras 
activation (Solomon et al., 2012) and to cooperate with RAS to drive MET receptor recycling 
(Muller et al., 2013), enhancing MAPK activation and accelerating cell proliferation, scattering, 
and invasion. Similarly, mutant p53 up-regulates platelet-derived growth factor receptor β 
(PDGFR-β)(Weissmueller et al., 2015), and reprograms the response of cancer cells to TGF-β 
(Adorno et al., 2009). In addiction, mutant p53 cooperates with the SWI/SNF complex to 
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remodel the chromatin architecture of the VEGFR2 promoter, leading to enhanced VEGFR2 
expression and pathway activity (Pfister et al., 2015). Finally, mutant p53 enhances the cell 
response to an inflammatory microenvironment, amplifying NF-κB activation and transcriptional 
function, leading to an increased rate of transformation (Cooks et al., 2014)(Weisz et al., 2007).  
 
3.5 Mutant p53 promotes PI3K/AKT pathway activation 
The PI3K/AKT (PKB) pathway is a fundamental signaling axis that controls cell responses to 
metabolic, survival, and growth signals. Not surprisingly, as described above, dysfunctional 
PI3K/AKT cascade is commonly observed in metabolic diseases and in multiple tumors. Indeed, 
PI3K/AKT pathway hyperactivation confers an enormous advantage to cancer.  
In this context, mutant p53 gains from its activation to sustain cancer development. Indeed, it has 
been reported that mutant p53 can enhance PI3K/AKT pathway activation in human endometrial 
cancer cells (EC), promoting invasion ability. In particular, over-expression of p53-R175H leds 
to enhanced EGFR phosphorylation, and subsequently activation of PI3K/AKT pathway, but has 
no effect on the MEK/ERK pathway. Moreover, abolished p53-R175H-induced cell invasion and 
migration and attenuated activation of AKT upon treatment with EGFR inhibitor, suggest that 
GOF effects of this mutant could drive invasive characteristics in EC cells through 
EGFR/PI3K/AKT-dependent pathway (Dong et al., 2009). Overall, the results of this study show 
the possibility that GOF activity of p53-R175H contributes to an aggressive phenotype to EC 
cells, at least in part through the ability of p53-R175H to associate with active EGFR, 
subsequently resulting in the activation of its downstream PI3K/AKT signaling pathway. 
Moreover, it has been demonstrated that RCP-dependent α5β1/EGFR trafficking augments 
EGFR phosphorylation, leading to increased AKT signaling (Caswell and Norman, 2008). 
Consistent with this, Vousden’s group showed that mutant p53 drives constitutive activation of 
EGFR, and its communication with AKT but not ERK. Indeed, upon expression of mutant p53, 
p63 transcriptional activity is suppressed, resulting in enhanced RCP-driven recycling of α5β1 
integrin and EGFR. Moreover, IHC staining of primary human colons showed a correlation 
between high expression of p53 (an indicator of the presence of mutant p53) and strong phospho-
AKT staining. These results suggest that mutant p53 specifically drives RCP-dependent 
recycling of integrin and EGFR resulting in alteration of AKT signaling, which contributes to 
increased invasion and metastasis (Muller et al., 2009). 
Finally, Tan’s group demonstrated that p53-R273H contact mutant suppresses BMF expression 
in a way that is dependent on PI3K/AKT signaling pathway promoting cancer cell survival and 
anoikis resistance (Tan et al., 2015). In particular, silencing of endogenous p53-R273H contact 
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mutant, but not p53-R175H conformational mutant, reduces AKT phosphorylation, induces 
BCL2-modifying factor (BMF) expression, sensitizes BIM dissociation from BCL-XL and 
induces mitochondria-dependent apoptosis in cancer cells. Importantly, cancer cells harboring 
endogenous p53-R273H mutant are inherently resistant to anoikis and lack BMF induction 
following culture in suspension. However, how exactly mutant p53 contributes to PI3K/AKT 
activation remains an open question. 
 
4. DAB2IP: GUARDIAN OF CYTOPLASMIC SIGNAL TRANSDUCTION 
 
4.1 The tumor suppressor DAB2IP 
DAB2IP is a tumour suppressor gene associated with ovarian (Fazili et al., 1999), prostate 
(Wang et al., 2002) and mammary cancer (Schwahn and Medina, 1998) as well as 
choriocarcinoma (Fulop et al., 1998). DAB2IP modulates several signal cascades controlling cell 
proliferation, survival, apoptosis and metastasis (Liu et al., 2016)(Bellazzo et al., 2016).  
DAB2IP is frequently down-regulated in tumours; however, its loss does not induce cancer 
formation per se, but strongly supports cell transformation induced by driver mutations in 
various oncogenic pathway (Bellazzo et al., 2016).  
DAB2IP was initially identified as a novel member of the RAS GTP-ase (RAS GAP) protein 
family, cloned specifically as a protein interacting with the tumor suppressor DOC-2/DAB2 
(differentially expressed in ovarian carcinoma-2/Disable-2). Concomitantly, DAB2IP has been 
identified as AIP1, ASK1-interacting protein. Playing as a competitor, AIP1 facilitates 
dissociation of 14-3-3 from ASK1 and it enhances ASK1-JNK pathway activation in response to 
TNF (Zhang et al., 2004)(Zhang et al., 2003). In addition to acting as a cytoplasmic Ras GAP, 
DAB2IP also functions as a signaling scaffold to modulate the cell’s response to multiple 
extracellular signals. 
 
4.2 The human DAB2IP gene 
The DAB2IP gene is located on human chromosome 9q33.1–q33.3 and spans approximately 96 
kb with 15 exons and 14 introns (Chen et al., 2002). It is highly polymorphic, and several reports 
indicate that genetic variation of DAB2IP is associated with the risk of cancer (Duggan et al., 
2007)(Hsieh et al., 2007). The gene is rather complex, and can express multiple transcripts and 
proteins. Two human transcripts and proteins are annotated in Ref Seq: hDAB2IP transcript 
variant 1 (NM_032552.3), and hDAB2IP transcript variant 2 (NM_138709.1). They are 
transcribed by different promoters, and encode predicted proteins that differ in their N-terminus 
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(variant 1 being 96 amino acids longer) and have an alternative C terminal exon (Chen et al., 
2002)(Chen et al., 2006). The hDAB2IP gene is ubiquitously expressed in different tissues and 
organs. During development, hDAB2IP is expressed in most human fetal tissues, in a gestational 
age- and tissue-type specific manner. Low levels of its transcript are found only in seminal 
vesicle, ventral prostate, epididymis, and bladder (Wang et al., 2002). hDAB2IP transcript 
variant 1 seems to be the dominant isoform expressed in normal tissues (Qiu et al., 2007).  
 
4.3 DAB2IP protein structure and interactions 
DAB2IP consists of several conserved structural domains, involved in the interaction with many 
different proteins, thus affecting the outcome of multiple cellular inputs. 
 
 
Figure 9: DAB2IP protein structure and interactors. Schematic representation of DAB2IP (isoform 2) domains. 
 
 
Pleckstrin homology domain (PH domain): an approximately 100-residue module, localized on 
the N-terminal of DAB2IP. This domain results in DAB2IP membrane targeting via the binding 
phosphatidylinositol lipids. Thus, PH domain is involved in the recruitment of different protein 
associated to membrane, driving their physiological localization and activity (Musacchio et al., 
1993).  
 
Protein kinase C conserved region 2 (C2 domain): a Ca2+ binding motif that in DAB2IP spans 
from 21 to 110 aa (Chen et al., 2002). This domain displays the remarkable property of binding a 
variety of different ligand and substrates such as Ca2+, phospholipids, inositol polyphosphates, 
and intracellular proteins. Not all proteins containing C2 domains are regulated by Ca2+, 
suggesting that some C2 domains may play a purely structural role (Nalefski and Falke, 1996). 
DAB2IP C2 domain interacts with several proteins involved in signal transduction such as ASK1 
(Zhang et al., 2003), GSK3β (Xie et al., 2010), VEFGR2 (Zhang et al., 2008). Indeed C2 domain 
binds mutant p53, counteracting the binding of DAB2IP with ASK1, preventing JNK 
phosphorylation and enhancing NF-κB activation in response to TNF (Di Minin et al., 2014). 
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PH-C2 domain: This domain is required for the regulation of the JAK/STAT pathway. DAB2IP 
binding to JAK2 inhibits its phosphorylation, STAT1 and STAT3 phosphorylation and activation 
upon IFNγ treatment functions, strongly reducing proliferation and migration of vascular smooth 
muscle cells (VSMC) (Yu et al., 2011). 
 
RasGTPase-activator protein (RasGAP domain): it is localized in the N terminus of DAB2IP 
and spans from 135 to 438 aa. The GAP domain is critical for the binding for Ras (Chen et al., 
2002), RIP (Zhang et al., 2007), HIPK1 (Li et al., 2005) and PP2A (Min et al., 2008).  
 
Proline rich domain (PR domain): it is a domain implicated in protein-protein interactions, in 
particular it is a docking site for proteins with SH3 domains (Feller et al., 1994). PR domain is 
involved in the binding with c-Src (Wu et al., 2013). Moreover, DAB2IP via its PR domain 
sequesters p85-p110 complex and inhibits PI3K activity and AKT activation (Xie et al., 2009). 
 
Period-like domain (PER domain): a non-described structure, involved in protein-protein 
interaction. PER domain binds TRAF2 (Zhang et al., 2004) and 14-3-3 proteins (Zhang et al., 
2007). Indeed, PER domain is involved in the binding of DAB2IP to AKT1 counteracing its 
activation (Xie et al., 2009). 
 
Leucine zipper domain: it is a hydrophobic motif, usually found within the DNA-binding 
domain of transcription factors. It is involved in the formation of protein dimers and is involved 
in DAB2IP binding to GATA-1 (Yun et al., 2014). 
 
4.4 DAB2IP: a broad modulator of multiple oncogenic pathways 
In various cell models, DAB2IP was shown to affect many signaling pathways relevant for 
cancer almost invariably acting to restrain their oncogenic outcomes. 
.  
For instance, DAB2IP can down-modulate canonical WNT signaling. DAB2IP sustains 
activation of GSK- 3β by reducing Serine 9 phosphorylation, with the help of PP2A recruited by 
DAB2IP in a ternary complex. The C2 domain interacts with both GSK-3β and PP2A, and 
facilitates GSK-3β activation to decrease nuclear β-catenin accumulation and its transcriptional 
activity (Min et al., 2008) (Xie et al., 2010). Perhaps the best characterized fucntion of DAB2IP 
is in TNF-α signaling. DAB2IP acts as a scaffold in TNF-induced recruitment of PP2A to ASK1 
complex, leading to dephosphorylation of ASK1 at pSer967 and activation of ASK1-JNK 
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signaling by the pro-apoptotic kinase (Min et al., 2008). Moreover, RIP in the DAB2IP complex 
mediates TNF-induced DAB2IP phosphorylation at 14–3–3-binding site (Ser604). Indeed, RIP1 
associates with the GAP domain of DAB2IP and synergizes DAB2IP-mediated JNK/p38 MAPK 
activation (Zhang et al., 2007). More importantly, DAB2IP associates with the effector domain 
(the RING finger) of TRAF2 through its PER domain and inhibits IKK- NF-κB signaling (Zhang 
et al., 2004). 
Another condition in which DAB2IP promotes ASK1-JNK/p38 signaling is during the Unfolded 
Protein Response (UPR). DAB2IP binds directly to a key mediator of the UPR, the inositol-
requiring enzyme-1 (IRE1α), facilitates its dimerization, behaving as a scaffold protein to 
mediate JNK phosphorylation by the kinase IRE1α (Luo et al., 2008). DAB2IP also inhibits JAK 
kinase activity, thus limiting JAK-dependent STAT1/3 and PI3K/AKT phosphorylation and 
activation in vascular smooth muscle cells. In non-muscle invasive bladder cancer, DAB2IP-
dependent inhibition of STAT3 has been reported to limit expression of Twist1 and P-
glycoprotein, crucial factors for chemoresistance (Wu et al., 2015). In prostate cancer cells, 
DAB2IP was found to directly bind STAT3, suppressing transactivation and expression of the 
anti-apoptotic target survivin. Finally, DAB2IP modulates constitutively active androgen 
receptor (AR) via PP2A-mediated inhibition of AR phosphorylation and nuclear translocation, 
thereby inhibiting AR transcriptional activities (Wu et al., 2014). Indeed, the unique PR domain 
in DAB2IP is capable of competing with AR to form complex with c-Src in PCa cells, inhibiting 
c-Src and ERK signaling pathway. 
 
 
Figure 10: DAB2IP modulates multiple signaling pathways. Schematic rappresentation of the main molecular pathways 
regulated by DAB2IP 
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4.4.1 DAB2IP modulates the Ras-MAPK pathway. 
One of the most important activities of DAB2IP is its function as a GTPase-Activating Protein 
for Ras. Ras proteins are monomeric GTPases strongly involved in cancer. Physiological or 
oncogenic activation of Ras induces a wide range of downstream effects; the best characterized 
is the RAF-MEK-ERK cascade, stimulating cell growth, 
proliferation, survival, and differentiation (Moodie et al., 
1993)(Pylayeva-Gupta et al., 2013). In addition to the MAPKs, 
Ras proteins can also activate PI3K, mediating proliferative 
and survival signals (Castellano and Downward, 2011). 
The GAP domain of DAB2IP is homologous to other Ras-
GAPs, such as GAP120 and neurofibromin (NF1), and can 
stimulate the GTPase activity of Ras proteins both in vitro and 
in cancer cell lines. For istance, Wang et al. showed that 
DAB2IP could interact with the N-terminal domain of DAB2 
protein directly and functions as a Ras GAP in vivo and in 
vitro (Wang et al., 2002). Through this activity, DAB2IP can 
also dampen Ras-induced activation of PI3K, contributing to inhibition of the PI3K–AKT 
signaling axis. 
 
4.4.2 DAB2IP regulates PI3K/Akt pathway   
Another important activity of DAB2IP, particularly relevant for this Thesis, is its function as an 
inhibitor of the PI3K/AKT signaling axis. The phosphatidylinositol 3-kinase/protein kinase-B/ 
mammalian target of rapamycin (PI3K/AKT/mTOR) 
signaling cascade is one of the most important intracellular 
pathways and is frequently activated in diverse cancers 
(Janku et al., 2012). It has a major impact on cell 
metabolism, size, proliferation, survival, and motility, and is 
frequently activated in cancer either by gain-of-function 
mutations, or by loss of function of the critical regulator 
PTEN (Fruman et al., 2014). As previous described, class I 
PI3K is divided into class I A group with its 110-kDa 
catalytic subunit (p110) and an 85-kDa regulatory subunit 
(p85) (Kok et al., 2009). The PR domain within DAB2IP can 
bind to the p85 regulatory subunit of class IA PI3K kinase, thus inhibiting its activation and 
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downstream signaling. In addition, DAB2IP binds to AKT via its PER domain, and such 
interaction inhibits Akt activation and function (Xie et al., 2009)(Valentino et al., 2017b). The 
GAP activity of DAB2IP can further enforce inhibition of the PI3K–AKT axis by reducing Ras-
dependent activation of the PI3K p110α subunit (Castellano and Downward, 2011)(Mendoza et 
al., 2011). Noticeably, DAB2IP dissociates ASK1 inhibitor 14-3-3 from its C terminus and then 
facilitates ASK1 activation (Zhang et al., 2003). Moreover, DAB2IP-mediated binding and 
inhibition of PI3K-AKT also contributes to ASK1 activation, under TNF-α treatment (Xie et al., 
2009). Indeed, DAB2IP interacts with either p85α or ASK1; however, a dramatic increase of 
complex formation was detected under either PI3K inhibitor or TNF-α treatment. In the ASK1-
DAB2IP-PI3K complex, the active form of ASK1 (T845) became more predominant than its 
inactive form (S83). In this complex, AKT activation is reduced, suggesting that DAB2IP might 
inhibit PI3K via a direct protein interaction with both PI3K and AKT. In a feedback loop, ASK1 
increases S604 phosphorylation in DAB2IP, which significantly enhances the binding ability of 
DAB2IP to AKT and PI3K complex. Interestingly, DAB2IP is also a target of AKT: by scanning 
the protein sequence, Dai et al. identified two consensus AKT sites (RxRxxpS/T) in the C 
terminus of DAB2IP at Serine-847 and Serine-907 (Dai et al., 2014). Phosphorylation by AKT 
reduces DAB2IP activity towards H-Ras and TRAF2, altering DAB2IP regulation of 
downstream effector pathways (Dai et al., 2014). 
Thus, enhanced AKT activation would inhibit DAB2IP, which would further fuel AKT 
activation in a potentially oncogenic positive feedback loop. 
 
4.5 DAB2IP inactivation enhances multiple oncogenic phenotypes 
DAB2IP has been implicated in the regulation of diverse biological processes including 
proliferation (Wang et al., 2002), apoptosis (Xie et al., 2009), survival (Luo et al., 2008)(Zhang 
et al., 2007), epithelial-to-mesenchymal transition (EMT) (Xie et al., 2010), cancer stem cell 
(CSC) (Yun et al., 2015), autophagy (Yu et al., 2012), and angiogenesis (Zhang et al., 2008).  
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Figure 11: DAB2IP influences the cancer cell’s response to a plethora of extracellular stimuli. 
DAB2IP protein modulates different cytoplasmic signaling pathways, regulating cancer cell response to inflammatory cytokines, 
growth factors and hormones that are present in the tumor microenvironment and are secreted from stromal and immune cells, 
and the tumor cell itself (Adapted from Bellazzo et al., 2017). 
 
Alterations of these processes are common features in cancer and DAB2IP functions as a bona 
fide tumor suppressor. 
Indeed, in human normal prostate epithelial and prostate carcinoma cells, as well as in clinical 
PCa specimens, loss of DAB2IP expression initiates EMT (Xie et al., 2010). Indeed, DAB2IP 
controls EMT and cell invasion by coordinating both the WNT/β-catenin and NF-κB pathways 
(Xie et al., 2009)(Min et al., 2010)(Min et al., 2015).  DAB2IP loss enhances chemoresistance in 
prostate cancer cells by upregulation of the anti- apoptotic protein clusterin (CLU) (Wu et al., 
2013), maybe linked to the loss of DAB2IP inhibitory action on EGF1 expression (Wu et al., 
2013). Similarly, loss of DAB2IP facilitates survival of prostate cancer cells after androgen 
deprivation therapy, by augmenting STAT3 activation and survivin expression (Yu et al., 2012). 
Moreover, DAB2IP inactivation may promote a hypoxia-like response, with upregulation of HIF 
target genes and increased expression and activity of VEGF proteins, affecting the cancer cell 
and its microenvironment, and promoting tumor vascularization (Li et al., 2015). Notably, 
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DAB2IP directly binds to VEGFR-2 and limits PI3K activation, thus functioning as endogenous 
inhibitor of adaptative angiogenesis (Zhang et al., 2008). 
DAB2IP knock out mice show enhanced inflammation in models of ischemic hind limb, graft 
arteriosclerosis, and inflammatory angiogenesis (Zhang et al., 2008) (Zhang et al., 2016)(Yu et 
al., 2011)(Huang et al., 2013). In hyperlipidemic ApoE−/− mice, DAB2IP KO increases 
secretion of inflammatory cytokines and augments macrophage infiltration, thereby inducing 
endothelial dysfunction and early phases of atherosclerosis (Huang et al., 2013). 
Interestingly, DAB2IP-depleted cells have increased mTOR-S6K pathway activation and 
autophagy, suggesting that in normal cells DAB2IP inhibits autophagy, and loss of such 
inhibition in cancer contributes to radiation resistance (Yu et al., 2012).  
Finally, Yun and colleagues demonstrated that loss of DAB2IP enriches CSCs characteristics in 
human PCa cells, facilitating the binding of GATA-1 to CD117 gene promoter while repressing 
CD117 transcriptional activity (Yun et al., 2015). In addition, loss of DAB2IP may further 
support PI3K-AKT-mTOR signaling activation, promoting acquisition of CSC phenotypes.  
 
4.6 Mechanisms of DAB2IP inactivation in cancer 
The tumor suppressor DAB2IP is rarely mutated in human cancers. Indeed, different 
mechanisms for DAB2IP inactivation have been identified. 
 
 
 
 
Figure 12: DAB2IP inactivation mediated by various mechanisms.  Epigenetic DAB2IP inactivation relies on promoter 
hypermethylation mediated by the EZH2–PRC2 complex. Various microRNAs have been described that can target the DAB2IP 
3′ UTR reducing protein expression. DAB2IP protein levels can be negatively regulated by the activity of the E3-ubiquitin 
ligases Fbw7, Skp2, and Smurf1. Phosphorylation by AKT1 can also inhibit DAB2IP functions. Finally, direct binding with p53 
mutant proteins interferes with other DAB2IP interactions (Adapted from Bellazzo et al., 2016). 
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 Not surprisingly, DAB2IP expression is frequently reduced by methylation in tumors (Chen et 
al., 2005)( (Yano et al., 2005). The main factor controlling DAB2IP gene methylation appears to 
be the PRC2 (polycomb-repressive complex-2)– EZH2 (Enhancer of Zeste homolog) complex 
(Chen et al., 2005). Recently, it has been reported that the transcription factor Snail can repress 
DAB2IP expression in colon cancer cells (Wang et al., 2015). Nonetheless, in many cancers the 
gene is not methylated, and post-transcriptional mechanisms of DAB2IP inactivation have been 
reported.  Indeed, recent studies identify Fbw7, Smurf1 and Skp2 E3 ubiquitin ligases involved 
in the regulation of DAB2IP turnover, promoting its degradation (Dai et al., 2014)(Li et al., 
2016)(Tsai et al., 2014). Inhibitory phosphorylation of DAB2IP is an other mechanism of 
inactivation. The kinase AKT1 can phosphorylates DAB2IP on Ser 847 within the proline-rich 
domain, inhibiting its functions (Dai et al., 2014). Since DAB2IP has a relatively long 3′ UTR 
sequence, it represents a good candidate for post-transcriptional silencing by micro-RNAs 
(miRNAs). MiRNAs 338, 889, 92b and 32 have been described to reduces DAB2IP levels in 
different tissues (Barik, 2008)(Xu et al., 2015)(Liao et al., 2015)(Huang et al., 2016). Finally, 
DAB2IP can be functionally inhibited by the binding with mutant p53 in the cytoplasm of cancer 
cells. For istance, mutant p53 inhibition of DAB2IP interferes with its functions, thus 
reprogramming the way of cancer cells to respond to inflammatory cytokines, in particular TNF-
α (Di Minin et al., 2014) and Insulin (Valentino et al., 2017a), inducing a pro-oncogenic 
behavior. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
AIM OF THE THESIS 
 
DAB2IP/AIP1 is a Ras GAP that functions as cytoplasmic adaptor in signal transduction. In 
particular, DAB2IP modulates TNFα signaling, promoting activation of the Ask1/JNK pathway 
while counteracting activation of NFkB (Xie et al., 2010). Moreover, DAB2IP modulates other 
oncogenic pathways such as PI3K/AKT and WNT/beta-catenin, and inhibits Epithelial-
Mesenchimal Transition (EMT) in cancer cells (Bellazzo et al., 2017). Not surprisingly, its 
expression is frequently reduced by methylation in tumors (Chen et al., 2003)(Yano et al., 2005). 
Nonetheless, in many cancers the gene is not methylated, and we and others have reported post-
transcriptional mechanisms of DAB2IP inactivation (Dai et al., 2014)(Xu et al., 2015). One of 
such mechanisms is interaction with mutant p53. 
Point mutation of p53 is a frequent event and a significant factor in cancer development and 
progression (Muller and Vousden, 2013). Mutant p53 proteins (mutp53) are very stable, and 
acquire oncogenic properties (gain of function) that increase metastasis, proliferation, and cell 
survival. Through transcriptional and non-transcriptional activities, mutant p53 fosters tumor 
progression by reinforcing and up-regulating multiple oncogenic pathways, including RAS-
MAPK, PI3K-AKT, β-catenin, and NF-κB (Aschauer and Muller, 2016). 
Our group recently discovered that gain-of-function mutp53 proteins can bind DAB2IP in the 
cytoplasm and interfere with its functions, thus reprogramming the way by which cancer cells 
respond to inflammatory cytokines, in particular TNF, and inducing a pro-oncogenic behavior 
(Di Minin et al., 2014). We are convinced that the mutant p53/DAB2IP interaction has even 
broader implications, modulating the response to additional extrinsic inputs; in fact, DAB2IP 
modulates other pathways directly or indirectly linked to inflammation. Due to its broad clinical 
impact, in this Thesis I decided to focus on insulin and the PI3K-AKT axis. 
As detailed in the introduction, DAB2IP binds and inhibits PI3K-p85, limiting AKT activation in 
response to various stimuli (Xie et al., 2009). DAB2IP also binds directly to AKT1, possibly 
contributing to its inhibition, and is also phosphorylated by AKT1 in a negative feedback loop 
(Dai et al., 2014). It is therefore legitimate to hypothesize that mutant p53, by binding DAB2IP, 
modifies the response to insulin, with effects on proliferation and survival. 
 
 
The aim of my Thesis is to define the relevance of the mutant p53/DAB2IP interaction in this 
context, and explore possible strategies to target this molecular axis to restore DAB2IP functions 
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in cancer cells. Elucidating the role of insulin in TNBC and in androgen-independent PCa 
initiation and progression, and identifying the molecular pathways involved in the response of 
cells to insulin, may improve the development of effective diagnostic and treatment strategies to 
provide benefits to specific patients subgroups. 
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RESULTS 
 
5.1 Mutant p53 amplifies the oncogenic activity of insulin in hormone-independent breast 
and prostate cancer cells 
To explore the potential role of mutant p53 in the response of cancer cells to insulin, we 
performed BrdU incorporation, cell proliferation, and matrigel invasion assays with two human 
cancer cell lines bearing different missense TP53 mutations: MDA-MB231 (triple negative 
breast cancer, p53R280K) and DU145 (androgen-independent prostate cancer, 
p53V274F/P223L). We performed our experiments using a supraphysiological concentration of 
insulin (0,5ug/ml), to mimic an hyperinsulinemic condition (De León and Stanley, 2013).  
We observed that insulin increases proliferation and enhances the invasive capabilities of these 
cells. Strikingly, depletion of endogenous mutant p53 prevented this effect, suggesting that such 
increase is strictly dependent on mutant p53 expression (Figure 13).  
Colony formation assays confirmed that mutant p53 enhances proliferation of cancer cells 
chronically exposed to insulin. Using Ras-transformed embryonic fibroblasts (MEFs) derived 
from p53 knock-out or mutant p53 (R172H) knock-in mice, we verified that insulin triggers an 
increase in cell proliferation only in MEFs expressing mutant p53. Together, these data indicate 
that mutant p53 can be a determinant of the pro-oncogenic response to insulin, potentially 
defining a novel mutant p53 gain of function (Figure 14). 
 
5.2 Mutant p53 mediates insulin-induced proliferation and invasion by enhancing 
activation of AKT 
To define a mechanism of action for mutant p53 in the response to insulin, we first verified 
expression of the insulin receptor (INSR) in our cell lines (Figure 15A). Next, we asked if 
mutant p53 may affect INSR expression: by RT-PCR we observed that mutant p53 depletion 
does not affect INSR levels (Figure 15 B,C). Moreover, under certain conditions such as increase 
in concentration, insulin can stimulate the insulin-like growth factor 1 receptor 
(IGF1R)(Novosyadlyy et al., 2011); so we also checked IGF1R expression in our cell models; 
interestingly, mutant p53 depletion reduced IGF1R levels in MDA-MB231 but not in DU145 
cells (Figure 15 B, C). The results in MDA-MB231 are consistent with previous studies 
reporting that mutant p53 promotes IGF1R transcription (Werner et al., 1996). However, the 
results in DU145 imply that IGF1R downregulation is not relevant for the observed phenotypes - 
a concept further supported by other evidences (Figure 20D and Figure 27C). 
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We next focused on insulin-induced activation of the PI3K/AKT pathway. Using the specific 
AKT inhibitor MK2206, we found that the increase in proliferation and invasion triggered by 
insulin is strictly dependent on AKT activity (Figure 16). This result proves that AKT is a key 
effector in this context, and implies that other pathways potentially activated by INSR (e.g. 
Ras/MAPK) are not sufficient for the observed phenotypes. 
Since a large body of literature shows that AKT2 activation enhances cell invasiveness and 
metastasis, while AKT1 plays a major role in cell proliferation and survival (Irie et al., 
2005)(Chau and Ashcroft, 2004), we decided to explore the distinct role of the two kinases in the 
observed phenotypes. 
We thus used specific siRNAs to knock-down either AKT1 or AKT2 in our model cell lines. 
Interestingly, AKT1 depletion abrogated insulin-induced cell proliferation while knockdown of 
AKT2 strongly reduced insulin-dependent invasion in breast cancer MDA-MB-231 cells (Figure 
17A, B). In contrast, AKT2 depletion abrogated insulin-induced cell proliferation, whereas both 
AKT1 and AKT2 were required for cell invasion in prostate cancer DU145 cells (Figure 17C, 
D). These results corroborate the notion of a distinct role for the two AKTs, possibly displaying 
tissue specific activities. In addition, they suggest that the mutant p53 could promote insulin-
induced activation of both AKT isoforms, dictating specific oncogenic features of different 
tumor types.  
 
Previous studies reported evidence of correlation between mutant p53 and enhanced AKT 
phosphorylation in breast, endometrial, and colon cancer (Dong et al., 2009)(Tan et al., 2015). 
We therefore asked whether mutant p53 might affect AKT activation in the specific context of 
insulin stimulation. Given the availability of reagents in our laboratory, we initially focused on 
AKT1; therefore, in the following chapters we will always refer to AKT1, except when 
specifically indicated. As shown in Figure 18A, knockdown of mutant p53 clearly reduced 
insulin-induced AKT phosphorylation in MDA-MB231 cells. Identical results were obtained 
with DU145 (Figure 18B). Similarly, insulin induced a stronger and prolonged AKT 
phosphorylation in mutant p53 knock-in versus p53 null MEFs (Figure 18C).  
 
In line with the mitogenic and migratory response, insulin-induced AKT activation correlated 
with phosphorylation of GSK3β and increased Cyclin D1 levels. Upon mutant p53 depletion, 
insulin still triggered a moderate and transient AKT phosphorylation, but p-GSK3β and Cyclin 
D1 were significantly lower at longer times (Figure 19 A,B), consistent with reduced cell 
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proliferation and invasion. Insulin-induced phosphorylation or accumulation of additional AKT 
targets was likewise impaired by mutant p53 depletion (Figure 19C). 
 
Since insulin can also trigger activation of the Ras-MAPK cascade (Belfiore and Malaguarnera, 
2011) (Taniguchi et al., 2006), we monitored ERK phosphorylation as a readout of this pathway. 
We found no significant change in ERK activation upon insulin treatment and/or mutant p53 
knockdown, thus confirming that mutant p53 affects specifically insulin-induced AKT activation 
in these cells (Figure 20 A,B).  
To verify if mutant p53 is sufficient to promote insulin-induced AKT activation, we stably 
expressed the p53R280K and p53R175H mutants in p53-null H1299 cells. As shown in Figure 
20C, mutant p53 knock-in cells displayed stronger and prolonged insulin-induced AKT 
activation. No relevant changes were detected in INSR or IGF1R mRNA (Figure 20D), thus 
excluding an effect on receptor levels. We conclude that mutant p53 establishes a pro-oncogenic 
response to insulin by specifically favoring or enhancing the activation of AKT. 
 
5.3 Mutant p53 enhances insulin-induced AKT activation by inhibiting DAB2IP 
We previously discovered that mutant p53 proteins can bind the tumor suppressor DAB2IP in 
the cytoplasm, interfering with its functions (Di Minin et al., 2014). Since DAB2IP can modulate 
both PI3K and AKT (Xie et al., 2009), we hypothesized that the mutant p53-DAB2IP interaction 
may also affect the response to insulin. We therefore tested if depletion of DAB2IP could rescue 
the effects of mutant p53 knockdown in our cell models. Indeed, silencing of DAB2IP fully 
restored insulin-induced proliferation and invasion in mutant p53-depleted MDA-MB231 cells 
(Figure 21A). Similarly, depletion of DAB2IP restored the kinetics of insulin-induced AKT 
phosphorylation after mutant p53 knockdown (Figure 21B and 21C). Notably, knockdown of 
DAB2IP had a negligible impact on insulin-induced phenotypes in the presence of mutp53, thus 
confirming the epistatic relationship between the two proteins. In the same experimental settings, 
DAB2IP overexpression reduced insulin-dependent AKT phosphorylation (Figure 21D), and 
fully abolished the increase in proliferation and invasion triggered by insulin (Figure 21E). 
 
If the effects of mutant p53 are exerted by binding and inhibiting DAB2IP, they should be 
independent of its nuclear functions. Accordingly, overexpression of a cytoplasmic variant of 
mutant p53 (p53R280K NLS) (Di Minin et al., 2014) fully restored insulin-induced 
proliferation and invasion in MDA-MB231 cells previously depleted of endogenous nuclear 
mutant p53 (Figure 22A), or stably overexpressing DAB2IP (Figure 22B). 
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The functional impact of the mutant p53/DAB2IP axis was also confirmed in HBL-100, a triple 
negative breast cancer cell line with wild-type (wt) p53. In these cells, DAB2IP knockdown 
significantly increased insulin-induced proliferation and invasion (Figure 23A), correlating with 
enhanced AKT activation (Figure 23B), confirming its modulatory role on this pathway. 
Intriguingly, also depletion of wild-type  p53 augmented insulin-induced AKT phosphorylation 
(Figure 23C), as well as proliferation and invasion in HBL-100 cells (Figure 23D), suggesting 
that loss of wild-type p53 can promote this signaling axis.  
 
Nonetheless, expression of mutant p53 proteins (p53R175H or p53R280K) in HBL-100 cells had 
a much stronger effect than wild-type p53 depletion (Figure 24) on insulin-induced oncogenic 
responses, thus formally confirming a proper mutant p53 gain of function. Most importantly, the 
same was observed with expression of nuclear-excluded p53 mutants (Figure 24), confirming 
that this phenotype does not involve transcriptional activities of mutp53. 
 
5.4 Cytosolic wild type p53 can interact with DAB2IP 
The observation that wild-type p53 depletion enhances insulin-induced responses in HBL-100 
cells (Figure 23) raised the question as to whether this effect might also involve DAB2IP. In fact, 
our group previously reported that DAB2IP can interact with wild-type p53 when co-transfected 
in recipient cells (Lunardi et al., 2010). To address this point, we first evaluated if a cytosolic 
version of wild type p53 could promote insulin signaling, thus acting to some extent as a “mutant 
p53”. This also because in tumors there are occasional C-terminal mutations that are predicted to 
translate a truncated p53 protein lacking the NLS sequences. 
We thus generated an expression vector encoding wtp53 ∆NLS (Delta-NLS), and transfected this 
construct in p53-null H1299 cells. Interestingly, wtp53 ∆NLS appreciably increased insulin-
induced AKT activation, although not as efficiently as cytoplasmic mutant p53 R280K ∆NLS. 
However, cytoplasmic wtp53 did not affect insulin-induced phosphorylation of GSK3β, which 
instead was strongly enhanced by cytoplasmic mutant p53 (Figure 25A). 
Moreover, we found that wtp53 ∆NLS often bound with less efficiency/stability than mutp53 
∆NLS, despite comparable expression levels and cellular localization (Figure 25B and C). 
Thus, it appears that mutant p53 might have a higher affinity for DAB2IP than wild-type p53, 
although this kind of simple co-IP experiments cannot formally prove it. 
Based on these preliminary results, we conclude that high levels of cytoplasmic wtp53 can 
promote a transient insulin-induced AKT activation, possibly by interacting with DAB2IP. 
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5.5 Disruption of the mutant p53-DAB2IP interaction reduces the aggressive behavior of 
cancer cells exposed to insulin 
DAB2IP can bind both PI3K-p85α and AKT1 to negatively regulate AKT activation (19). On 
this premise, we decided to test two hypotheses: i) that DAB2IP might also bind AKT2; ii) that 
mutant p53 might stimulate insulin-induced AKT activation by interfering with DAB2IP-PI3K 
and DAB2IP-AKT interactions. 
To this aim, we performed transient overexpression experiments: we found that increasing 
amounts of mutant p53 caused a progressive reduction in the fraction of DAB2IP that could be 
co-immunoprecipitated with PI3K, AKT1, and AKT2 (Figure 26 A,B and C). Analyzing 
endogenous proteins, we observed that depletion of mutant p53 in MDA-MB-231 cells increased 
the fraction of DAB2IP co-immunoprecipitated with AKT1 (Figure 26D), further supporting the 
notion that mutant p53 binds and inhibits DAB2IP in this cell line.  
 
We previously found that mutant p53 binds to the N-terminus of DAB2IP, and we demonstrated 
that a chimeric decoy protein in which the first 186 amino acids of DAB2IP are fused to GFP 
(eGFP-KA2) can disrupt the mutant p53-DAB2IP interaction, restoring endogenous DAB2IP 
functions in cancer cells (Di Minin et al., 2014). We therefore repeated proliferation and invasion 
experiments using MDA-MB231 cells stably expressing the eGFP-KA2 protein. The eGFP-KA2 
decoy had no obvious effects on basal cell proliferation and motility, but clearly abolished the 
increase in proliferation and invasion triggered by insulin (Figure 27A), also significantly 
reducing AKT activation (Figure 27B). Expression of eGFP-KA2 did not influence INSR or 
IGF1R transcription (Figure 27C), so its effect is not linked to reduced receptor levels. 
Importantly, depletion of DAB2IP rendered the eGFP-KA2 construct ineffective, demonstrating 
that the inhibitory action of the KA2 peptide is strictly dependent on DAB2IP action (Figure 
27D). 
 
Together, these data provide a mechanism by which mutant p53 proteins, blocking DAB2IP, can 
enhance insulin-induced AKT activation in cancer cells, potentially determining a more 
aggressive behavior under hyperinsulinemic conditions (Figure 28).  
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5.6 Increased AKT activation correlates with p53 mutation in breast cancers from obese 
patients 
The above results predict that hormone-independent tumors with mutant p53 should have 
stronger or prolonged AKT activation under conditions of hyperinsulinemia. To investigate such 
potential association, we analyzed triple-negative breast cancers from obese and non-obese 
patients, assuming an obesity-linked hyperinsulinemia in clinically overweight (BMI >30) 
subjects (Rothman, 2008). The presence of potential p53 gain-of-function mutations was inferred 
by strong p53 staining in immunohistochemistry, while AKT activation was determined by 
immunoreactivity to a phospho-AKT (S473) antibody. In line with previous reports (Tan et al., 
2015)(Muller et al., 2009), we confirmed a general correlation between p-AKT and mutant p53. 
In addition, we found a strong correlation between elevated p53 staining (i.e. p53 mutation) and 
high levels of phospho-AKT specifically in obese patients (Figure 29). These observations are 
consistent with our model, and support the notion that p53 mutation may amplify AKT activation 
in cancers that develop under obesity-linked conditions. Moreover, we did not evaluate INSR 
expression in these samples. Considering that wtp53 represses INSR promoter, affecting its 
expression in breast cancer cells (Webster et al., 1996), we can not exclude  an increase in INSR 
expression due to the loss of wtp53 function. 
 
 
The described results have been recently published ( E. Valentino, A. Bellazzo, G. Di Minin, 
D.Sicari, M. Apollonio, G. Scognamiglio, M. Di Bonito, G. Botti, G. Del Sal, L. Collavin. 
 “ Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor 
DAB2IP ”. PNAS, 2017, vol 114, 7623-7628.  
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Figure 13 
 
 
 
 
 
 
Figure 13: Mutant p53 dictates an oncogenic response to insulin in hormone-independent cancer 
cells. 
A-B) Mutant p53 is required for insulin-induced proliferation in cancer cells. A) MDA-MB231 and 
DU145 cells were transfected with indicated siRNAs for 48 hours, serum starved, treated with 0.5 ug/ml 
insulin for 24 or 48 hours, and labeled with BrdU for 2 hours. Graphs summarize the percentage of BrdU 
positive nuclei (mean ± SEM; n=3; ** P<0.01; *** P<0.001). Depletion of endogenous p53 was checked 
by western blot. B) MDA-MB231 and DU145 cells stably silenced for endogenous mutant p53 (shp53) 
were serum starved, treated with 0.5 ug/ml insulin for 24 or 48 hours, and then colored with Crystal 
Violet. Graphs summarize normalized optical density at 570 nm (mean ± SEM; n=3; ** P<0.01, *** 
P<0.001). Depletion of endogenous p53 was checked by western blot. 
C-D) Mutant p53 is required for insulin-induced invasion. Cells were transfected with indicated siRNAs 
for 48h, serum starved for 24h, and treated with insulin (0.5 ug/ml) for additional 24h. Invasion assays 
were performed in low serum plus 0.5 ug/ml insulin. C) Graphs summarize migrated cells per area (mean 
± SEM; n=3; ** P<0.01, *** P<0.001). Depletion of endogenous p53 was checked by western blot. D) 
Representative images of migrated cells from C, fixed and stained with Crystal Violet. 
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Figure 14 
 
 
 
 
 
Figure 14: Mutant p53 depletion reduces insulin-induced cell proliferation. 
A) Mutp53 sustains insulin-induced cell proliferation. MDA-MB231 and DU145 cells stably silenced for 
endogenous mutant p53 (shp53) were plated at low density and treated with 0.5 ug/ml insulin every 48 
hours for 10 days. Petri dishes were photographed after Giemsa staining (representative pictures are 
shown), and colony formation efficiency was quantified using ImageJ (mean ± SEM; n=3; * P<0,1 ; ** 
P<0.01). 
B) Mutp53 drives insulin-induced proliferation in Ras-transformed mouse embryo fibroblasts (MEF). 
MEFs derived from p53-null (-/-) or p53R172H knock-in (m/m) mice were treated and analyzed as in Fig. 
1A (mean ± SEM; n=3; ** P<0.01). Expression of p53 was checked by western blot. 
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Figure 15 
 
 
 
 
 
 
 
Figure 15: Mutant p53 depletion reduces insulin-induced cell proliferation without affecting 
expression of insulin receptors. 
A) Expression of INSR in various human cancer cell lines. Expression of INSR A/B was measured by 
RT-qPCR (n=1) in the indicated cell lines. HL-60 and Malahawu cell lines were analyzed respectively as 
negative (low INSR expression) and positive (high INSR expression) controls. 
B-C) Effects of mutant p53 depletion on expression of insulin receptors. MDA-MB-231 and DU-145  
cells were transfected with indicated siRNAs. Expression of INSR A/B and IGF1R was measured by RT-
qPCR (mean ± SEM; n = 3; ** P<0.01 ). Immunoblotting confirmed depletion of endogenous mutant 
p53. 
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Figure 16 
 
 
 
 
 
 
 
 
Figure 16: Mutant p53 increases insulin-induced proliferation and migration through AKT 
activation. 
A-B) Insulin-induced cell proliferation and invasion require AKT activity. A) MDA-MB231 cells were 
transfected with indicated siRNAs for 48 hours, serum starved, and treated with insulin (0.5 ug/ml) for 24 
hours, with or without the specific AKT inhibitor MK2206 (5 uM). B) Cells were serum starved and 
treated with insulin (0.5 ug/ml) for 24 hours, with or without the specific AKT inhibitor MK2206 (5 uM). 
Proliferation and invasion assays were performed as in Figure 13 (mean ± SEM; n=3; **P<0.01, 
***P<0.001). C-D) Insulin-induced cell proliferation and invasion require AKT activity. DU-145 cells 
were serum starved and treated with insulin (0.5 ug/ml) for 24 hours, with or without the specific AKT 
inhibitor MK2206 (5 uM). Proliferation and invasion assays were performed as in Figure 1 (mean ± SEM; 
n=3; ***P<0.001). 
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Figure 17 
 
 
 
 
 
Figure 17: Insulin-induced cell proliferation and invasion can be driven by different AKT family 
members. 
A and C) Insulin-induced cell proliferation. MDA-MB231 and DU-145 cells were treated with indicated 
siRNA for 48h, serum starved for 24h, treated with insulin (0.5 ug/ml) for additional 24h and labeled with 
BrdU for 2 hours. Graphs summarize the percentage of BrdU positive nuclei (mean +/- SD; n=3; *** 
P<0.001). B and D) Insulin-induced matrigel invasion. MDA-MB231 and DU-145 cells were treated with 
indicated siRNA for 48h, serum starved for 24h, and treated with insulin (0.5ug/ml) for additional 24h. 
Invasion assays were performed in low serum plus 0.5 ug/ml insulin. Graphs summarize migrated cells 
per area (mean +/- SD; n=3; ** P<0.01). Depletion of endogenous AKT1 and AKT2 was checked by 
western blot and RT-qPCR analysis (not shown). 
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Figure 18 
 
 
 
 
 
 
Figure 18: Mutant p53 increases AKT activation. 
A) Depletion of mutant p53 reduces insulin-induced AKT activation in cancer cells. MDA-MB231 cells 
were transfected with indicated siRNAs for 48 hours, serum starved for 24 h, and treated with insulin (0.5 
ug/ml) for the indicated times. Phosphorylated (p-T308 and p-S473) and total AKT1 were detected by 
immunoblotting. p53 was blotted to control knockdown efficiency, with Actin as a loading control.  
p-AKT S473  is taken from a different gel, loaded in parallel with the same amount of lysate.  
B) Depletion of mutant p53 reduces insulin-induced AKT activation in DU-145. Cells were transfected 
with control or p53 siRNA for 48 hours, serum starved for 24 h, and treated with insulin (0.5 ug/ml) for 
the indicated times. Phosphorylated and total AKT1 were detected by immunoblotting. p53 was blotted to 
verify knockdown efficiency, with Actin as a loading control. 
C) Insulin-induced AKT activation is enhanced in mutant p53 knock-in MEFs. Ras-transformed mouse 
embryo fibroblasts derived from p53-null (-/-) or p53R172H knock-in (m/m) mice were used to analyze 
Insulin-induced AKT (p-S473) activation. Phosphorylated and total AKT1 were detected by 
immunoblotting. p53 was blotted to verify knock-in efficiency, with Actin as a loading control. 
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Figure 19 
 
 
 
 
 
 
 
 
 
 
Figure 19: Mutant p53 increases AKT pathway activation. 
A) Depletion of mutant p53 affects prolonged AKT-dependent responses to insulin. MDA-MB231 cells 
were treated as in Figure 18A. Phosphorylated and total AKT1, GSK3β and CyclinD1 were detected by 
immunoblotting as above. p53 was blotted to control knockdown efficiency, with Actin as a loading 
control. Total AKT is taken from a different gel, loaded in parallel with the same amount of lysate.  
B) Depletion of mutant p53 reduces insulin-induced phosphorylation of GSK3β and accumulation of 
cyclin D1. Graphs summarize relative p-GSK3β S9/GSK3β and CycD1/actin ratios in MDA-MB231 cells 
treated with insulin for the indicated times (representative blots are in A), as measured by densitometry on 
autoradiography film (average ± SEM, n=3). C) Depletion of mutp53 affects insulin-induced AKT-
dependent molecular responses. MDA-MB-231 cells were treated as in Figure 18A. Phosphorylated and 
total Akt1, S6RP, p70S6K and c-Myc were detected by immunoblotting. p53 was blotted to control 
knockdown efficiency, with Actin as a loading marker. 
 
 
48 
Figure 20 
 
 
 
Figure 20: Mutant p53 increases AKT pathway activation without affecting INSR expression. 
A-B) Depletion of mutant p53 has no detectable effects on MAPK activation in insulin-treated cancer 
cells. MBA-MD231 and DU-145 cells were treated as in figure 18A. Phosphorylated and total AKT1 and 
ERK were detected by immunoblotting. p53 was blotted to verify knockdown efficiency, with Actin as a 
loading control.C) Mutant p53 enhances insulin-induced AKT activation. H1299 cells (p53 null) were 
infected with retroviruses encoding the indicated p53 mutants. Cells were treated with insulin (5ug/ml) 
for the indicated time. Phosphorylated and total AKT1 and GSK3β were detected by immunoblotting. p53 
was blotted to verify expression levels, with Actin as a loading control. D) Effects of mutant p53 
overexpression on INSR and IGF1R mRNA levels. H1299 p53-null cells were infected with retroviruses 
expressing the indicated mutant p53 proteins. Expression levels of INSR A/B and IGF1R were measured 
by RT-qPCR (mean ± SEM; n = 3; * P<0,1). Immunoblotting confirmed expression of exogenous mutant 
p53 proteins. 
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Figure 21: Functional interaction between mutant p53 and DAB2IP in the response of cancer cells 
to insulin. 
A) Epistasis between mutant p53 and DAB2IP in insulin-induced proliferation and invasion. MDA-
MB231 cells were silenced for mutant p53 and/or DAB2IP for 48 hours, and treated with 0.5 ug/ml 
insulin for 24h. Proliferation (top) and invasion (bottom) assays were performed as in Figure 13 (mean ± 
SEM; n=3; ** P<0.01; **** P<0.0001). 
B and C) Epistasis between mutant p53 and DAB2IP in insulin-induced AKT activation. MDA-MB231 
cells were silenced for mutant p53 and/or DAB2IP for 48h, serum starved for 24h, and treated with 
insulin (0.5 ug/ml) for the indicated times. Phosphorylated and total AKT1 were detected by 
immunoblotting.  
D) DAB2IP overexpression reduces insulin-induced AKT activation in mutant p53 cancer cells. MDA-
MB231 cells stably transduced with a retrovirus expressing DAB2IP were serum starved and treated with 
insulin (0.5 ug/ml) for the indicated times. Phosphorylated and total AKT1 were detected by 
immunoblotting. Total AKT is taken from a different gel, loaded in parallel with the same amount of 
lysate. E) DAB2IP overexpression reduces insulin-dependent proliferation and invasion in mutant p53 
cancer cells. MDA-MB-231 cells stably transduced with a DAB2IP retrovirus were serum starved and 
treated with insulin (0.5 ug/ml) for 24 hours. Proliferation (left) and invasion (right) assays were 
performed as in Figure 13 (mean ± SEM; n=3; ** P<0.01; *** P<0.001). Expression of endogenous and 
exogenous DAB2IP was checked by western blot. 
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Figure 22 
 
 
 
 
 
 
 
 
 
 
Figure 22: A cytoplasmic mutant p53 drives the oncogenic response to insulin. 
A-B) Insulin-induced proliferation and invasion are mediated by cytoplasmic mutant p53. A) MDA-
MDA-MB231 cells stably silenced for endogenous mutant p53 (shp53) were infected with retroviruses 
encoding shRNA-resistant versions of p53(R280K) or its cytoplasmic variant p53(R280K)NLS. 
Proliferation (top) and invasion (bottom) assays were performed as in Figure 13 (mean ± SEM; n=3; ** 
P<0.01). B) MDA-MB231 cells stably overexpressing DAB2IP were infected with a retrovirus expressing 
HA-p53(R280K)NLS or an empty retrovirus as a control. Proliferation (top) and invasion (bottom) 
assays were performed as in Figure 13 (mean ± SEM; n=3; ** P<0.01, **** P<0.0001). 
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Figure 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
Figure 23: Functional interaction between p53 and DAB2IP in the response to insulin of breast 
cancer cells with wild-type p53. 
A) DAB2IP knockdown enhances insulin-induced proliferation and migration in wt p53 cancer cells. 
HBL-100 were transfected with indicated siRNAs for 48 hours. Proliferation (top) and invasion (bottom) 
assays were performed as in Figure 13 (mean ± SEM; n=3; *P<0.1 ; *** P<0.001; ****P<  0.0001). 
Efficiency of endogenous DAB2IP depletion was checked by western blot.  
B) DAB2IP knockdown enhances insulin-induced AKT activation in wt p53 cancer cells. HBL-100 cells 
were transfected with control or DAB2IP siRNA for 48 hours, serum starved for 24 h, and treated with 
insulin (0.5 ug/ml) for the indicated times. Phosphorylated (p-S473) and total AKT1 were detected by 
immunoblotting. DAB2IP was blotted to verify knockdown efficiency, with Actin as a loading control.  
C) wt p53 depletion enhances insulin-induced AKT activation in HBL-100. Cells were transfected with 
control or p53 siRNA for 48 hours, serum starved for 24 h, and treated with insulin (0.5 ug/ml) for the 
indicated times. Phosphorylated (p-S473) and total AKT1 were detected by immunoblotting. p53 was 
blotted to verify knockdown efficiency, with Actin as a loading control. 
D) wt p53 depletion promotes insulin-induced proliferation and migration in HBL-100. Cells were 
transfected with control or p53 siRNA for 48 hours, serum starved for 24 h, and treated with insulin (0.5 
ug/ml) for the indicated times. Proliferation (left) and invasion (right) assays were performed as in Figure 
13 (mean ± SEM; n=3; ** P<0.01; *** P<0.001; ****P<0.0001). Expression of endogenous and 
exogenous p53 proteins was verified by immunoblotting, with Actin as a loading control. 
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Figure 24: Mutant p53 dominantly enhances insulin-induced proliferation and migration in wt p53 
cancer cells via a nuclear-independent activity.  
HBL-100 cells were infected with retroviruses encoding p53(R175H) and p53(R280K), and their 
respective cytoplasmic variants (∆NLS). As a control, cells were infected with a retrovirus expressing a 
p53-specific shRNA. Proliferation (left) and invasion (right) assays were performed as in Figure 13 (mean 
± SEM; n=3; ** P<0.01; *** P<0.001; ****P<0.0001). Expression of endogenous and exogenous p53 
proteins was verified by immunoblotting, with Actin as a loading control. 
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Figure 25 
 
 
 
 
 
Figure 25: Effects of cytoplasmic wild-type p53 on insulin-induced AKT activation. 
A) H1299 (p53-null) cells were transfected with expression vectors encoding nuclear-excluded (∆NLS) 
variants of wild-type and mutant p53 as indicated. After starvation, cells were treated with insulin 
(5ug/ml) for the indicated times. Phosphorylated and total AKT1 and GSK3β were detected by 
immunoblotting. Exogenous p53 was blotted to verify expression levels. Actin provided a loading 
control. B) Cytoplasmic localization of nuclear-excluded wt and mutant p53 (red) in transfected H1299 
cells was confirmed by immunofluorescence. DNA was counterstained with Hoechst 33342. C) H1299 
cells were co-transfected with the indicated expression plasmids. The fraction of DAB2IP bound to 
different p53 variants was analyzed by western blot of p53 immunoprecipitates. 
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Figure 26:  Mutant p53 hinders the interaction of DAB2IP with PI3K-p85α and AKTs.  
A-B-C) Mutant p53 displaces the inhibitory binding of DAB2IP with PI3K-p85α and AKTs. A) H1299 
cells were co-transfected with plasmids expressing DAB2IP, FLAG-PI3K-p85α and increasing amounts 
of p53 (R280K). The fraction of DAB2IP bound to PI3K was analyzed by western blot of PI3K 
immunoprecipitates. B) H1299 cells were co-transfected with plasmids expressing DAB2IP, HA-AKT1, 
and increasing amounts of p53 (R280K). The fraction of DAB2IP bound to AKT1 was analyzed by 
western blot of AKT immunoprecipitates. C) H1299 cells were co-transfected with plasmids expressing 
DAB2IP, HA-AKT2, and increasing amounts of p53 (R280K). The fraction of DAB2IP bound to AKT2 
was analyzed by western blot of AKT immunoprecipitates. D) MDA-MB231 cells were stably silenced 
for endogenous mutant p53 (shp53); endogenous DAB2IP bound to AKT1 was analyzed by co-
immunoprecipitation with anti-AKT1 antibody. 
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Figure 27:  Blocking mutant p53-DAB2IP interaction inhibits the oncogenic response to insulin 
without affecting the expression of insulin receptors. 
A) MDA-MB231 cells were stably transduced with retroviruses expressing the eGFP-DAB2IP (1-186) 
KA2 fusion protein (eGFP-KA2) or eGFP alone. Proliferation assays (left) and invasion assays (right) 
were performed as in Figure 13 (mean ± SEM; n=3; ** P<0.01, *** P<0.001). Expression of eGFP 
proteins was analyzed by western blot. 
B) MDA-MB231 cells stably transduced as in A were treated with insulin (5ug/ml) for the indicated 
times. Phosphorylated and total AKT1 were detected by immunoblotting. Expression of eGFP proteins 
and endogenous DAB2IP were verified by western blot. Asterisk indicates a non-specific reactive band.  
C) MDA-MB231 cells were stably transduced as in A. Expression of INSR A/B and IGF1R was 
measured by RT-qPCR (mean ± SEM; n = 3). Expression of eGFP proteins was analyzed by western blot. 
D) MDA-MB231 stably transduced as in A were transfected with the indicated siRNAs. Proliferation 
assays (top) and invasion assays (bottom) were performed as in Figure 13 (mean ± SEM; n=3; ** P<0.01, 
*** P<0.001). Expression of eGFP proteins and endogenous DAB2IP were verified by western blot. 
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Figure 28 
 
 
 
 
 
Figure 28: Proposed model for the gain of function of mutant p53 in the response to insulin.  
Mutant p53 gain of function is mediated by its cytoplasmic interaction with DAB2IP, promoting an 
oncogenic response to insulin. A competitor decoy protein (KA2) can restore DAB2IP inhibitory 
functions in cells with mutant p53. 
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Figure 29: AKT activation correlates with p53 mutation in TNBC of obese patients. 
A) Immunostaining with antibodies against p53 and p-AKT S473 of representative triple negative breast 
cancer sections derived from obese and non obese patients (H = Hematoxylin staining. Scale bar = 100 
m). B) Graphs summarize p-AKT S473 staining in tumor samples from 32 obese patients (BMI >30) 
and 20 non obese patients, sorted according to p53 status. Horizontal bar indicates the median. 
Correlations were analyzed by non-parametric Mann-Whitney U-test. C) Table summarizes the same 
tumor samples as in B, grouped according to p53 status and p-AKT S473 staining. Tumors with a p53 
staining > 80% have been classified as “mutant p53”. Tumors with p-AKT staining > 15% have been 
classified as “positive”. Correlations were analyzed by parametric Pearson’s Chi-square test (P-val). 
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DISCUSSION 
Pointing out a correlation among metabolic syndrome, obesity, diabetes, and increased incidence 
of various malignancies, several epidemiological studies demonstrated that hyperinsulinemia 
represents an important factor of risk in cancer progression (Giovannucci et al., 2010)(Wolin et 
al., 2010). 
 Obese and type 2 diabetic patients display high-doses of circulating insulin in the plasma 
(Cantiello et al., 2015)(Joost, 2014). Insulin, and host circulating hormones, in general, can have 
a dramatic impact on cancer growth and dissemination, acting directly on transformed cells as 
well as indirectly affecting the tumor microenvironment and the immune system (Gupta and 
Tikoo, 2013). 
We found that p53 mutation can significantly increase proliferation and invasion of cancer cells 
exposed to insulin. This was observed with different missense mutations, and could be 
recapitulated using a nuclear-excluded mutant p53. Therefore, this phenotype defines a novel 
cytoplasmic gain of function for mutant p53. This phenotype also indicates that a significant part 
of the oncogenic potential of mutant p53 – i.e. its gain-of-function - involves distorting the cell’s 
response to various extracellular inputs. This may be exerted at the transcriptional level, 
changing the transcriptional response to a multitude of pathway, and also – notably – at the 
cytoplasmic level, affecting various signal transduction steps. 
We found that cancer cells with high levels of mutant p53 have a stronger PI3K/AKT response 
to insulin because DAB2IP functions are limited by aberrant interaction with mutant p53. This 
discovery provides a molecular mechanism for previously reported correlations between p53 
mutation and AKT hyperactivation in cancer (Muller et al., 2009)(Tan et al., 2015). Intriguingly, 
it also suggests a mechanism by which TP53 mutation could surrogate for PI3K mutation, at 
least under some conditions. This would be in line with evidence that PI3K and TP53 alterations 
tend to be mutually exclusive in various carcinomas, including breast (Ciriello et al., 
2016)(Boyault  et al., 2012).  
Moreover, other possible explanation for the observed enhancement of insulin signaling by 
mutant p53 need to be considerated. 
Independent studies demonstrated that mutant p53 can induce the expression of IGF1-R (Werner 
et al., 1996) and wtp53 represses INSR promoter, regulating its expression in breast cancer cells 
(Webster et al., 1996). Moreover, at supraphysiological concentrations, insulin and IGF-1 cross-
react with each other’s receptors (Muniyappa and Sowers, 2012). Indeed, we evaluated mutant 
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p53 action on INSR and IGF1-R expression. We found that INSR mRNA levels are not affected 
by mutant p53 depletion. In contrast, IGF1R mRNA levels decreased after mutant p53 silencing 
in MDA-MB231 cells, in line with Werner et al. 
However, IGF1R mRNA levels were not affected by mutant p53 depletion in DU145 cells. We 
don’t know the basis of this discrepancy; it may be due to different levels/activity of other p53-
family members, p63 and p73, that can also repress IGF1R transcription (Werner et al., 1996), or 
it may reflect specific activities of the different p53 mutations in the two cell lines. In any case, 
this observation argues against a relevant impact of IGF1R in the observed phenotypes, since 
mutant p53 depletion in DU145 strongly inhibits insulin-induced p-AKT when IGF1R levels are 
not reduced. Additional evidences indicate that down-regulation of IGF1R is not relevant for our 
phenotypes: first, both INSR and IGF1R are not significantly increased by mutant p53 
overexpression in H1299, while insulin-induced AKT phosphorylation is augmented. Second, 
both INSR and IGF1R are not affected by overexpression of the eGFP-KA2 decoy protein in 
MDA-MB231 cells, while insulin-induced AKT phosphorylation is clearly reduced. These 
evidences can not exclude an action of hight insulin concentration on IGF1-R, moreover it is 
extremely unlikely that mutantp53-dependent regulation of IGF1R contributes significantly to 
our phenotypes. 
From a molecular point of view, our data raise interesting questions regarding the biochemical 
nature of the inhibitory action of DAB2IP on the PI3K/AKT axis, which is likely based on 
physical interaction but still needs to be defined.  
Another interesting question concerns the possible reciprocal modulation of DAB2IP by AKT. In 
fact, AKT1 can phosphorylate DAB2IP in the C-terminal proline-rich (PR) domain, and this 
phosphorylation reduces DAB2IP interaction with Ras and TRAF2, thus limiting its functions 
(Dai et al., 2014). Notably, the PR domain is also the site of interaction with p85, so 
phosphorylation by AKT may reduce the inhibitory action of DAB2IP on PI3K, further 
increasing AKT activation. Although not formally proved, it is plausible that a reciprocal 
regulatory circuit between DAB2IP and AKT indeed exists. 
We and others confirmed that the signaling protein DAB2IP negatively regulates the PI3K/AKT 
signaling pathway. In this perspective, therefore, DAB2IP is somehow similar to PTEN, a lipid 
phosphatase that dephosphorylates PtdIns (3,4,5)P3, or to PP2A, a ser/thr phosphatase that 
dephosphorylates AKT. In several cancers, downregulation or loss of function of these tumor 
suppressors can foster a pro-oncogenic response to insulin (Blanco-Aparicio et al., 
2007)(Włodarski et al., 2006)(Brognard et al., 2007). 
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It is tempting to speculate that DAB2IP may act as a buffer to limit activation of the PI3K/AKT 
axis in cancer cells that bear PI3K or PTEN mutations. Different levels of DAB2IP may thus 
explain differences in aggressiveness and response to therapy in cancers bearing identical PTEN 
or PI3K mutations. 
In the past, it has been reported that DAB2IP can also bind wild-type p53, at least in vitro or in 
overexpression (Lunardi et al., 2010), and this raises the question as to whether such interaction 
might have a biological impact on PI3K/AKT activation. We tried, but could not detect 
interaction of the endogenous proteins in multiple cell lines (Di Minin et al., 2014), so this 
hypothesis is unlikely. However, we cannot exclude that wt p53 might bind to DAB2IP under 
specific conditions that strongly increase cytoplasmic p53 levels. Clearly, additional studies will 
be required to test this possibility and its potential implications on the PI3K/AKT axis. 
 
Finally, we must consider that humans have three related AKT genes, encoding structurally 
related kinases with similar mechanism of activation and partially overlapping but distinct 
biological effects (Dillon and Muller, 2011); in this Thesis we focused on AKT1, but we 
performed some experiments and confirmed that DAB2IP can efficiently bind AKT2, and that 
mutant p53 interferes with this interaction. 
We also uncovered that AKT1 and AKT2 have a different action in mediating oncogenic 
responses to insulin in breast cancer (MDA-MB231 cells), while they share similar activity in 
prostate cancer (DU145 cells). The reasons for such differences are unknown, but are possibly 
linked to the presence or absence of specific AKT substrates differentially expressed in the tested 
cell lines. Indeed, how the three AKT proteins differ in their regulation, localization, and 
substrate utilization remains largely unknown. 
In any case, it is legitimate to assume that the cellular phenotypes reported in this Thesis are 
possibly mediated by both AKT1 and AKT2, hyper-activated in the presence of mutant p53. 
  
Several epidemiological studies reveal a direct correlation between obesity and breast and 
prostate cancer initiation and progression (Rostoker et al., 2013)(Weinstein et al., 2014). 
Interestingly, it has been observed that ER-positive breast cancer cells that develop resistance to 
Tamoxifen become more sensitive to INSR depletion or pharmacologic inhibition (Chan et al., 
2016), revealing the importance of insulin signaling to surrogate the mitogenic activity of 
estrogen. Indeed, tumors deprived from hormones, or other growth-factors, can potentially 
benefit from the oncogenic action of insulin. 
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Considering that mutp53 also impacts the response of cancer cells to inflammatory cytokines 
(Di Minin et al., 2014)(Cooks et al., 2014), it is plausible that p53 mutation might significantly 
increase growth and dissemination of endocrine-resistant metastatic cancer cells in patients with 
clinical, metabolic, or dietary conditions leading to hyperinsulinemia. Especially in conditions of 
obesity, where hyperinsulinemia is frequently coupled to chronic inflammation.  
From a clinical point of view, our results suggest that mutation of p53 could potentially affect the 
outcome of tumors that arise - or progress - under conditions of hyperinsulinemia. By looking at 
a set of clinical samples from the “Fondazione Pascale” in Napoli, we found a strong correlation 
between p53 mutation and AKT phosphorylation, specifically and selectively in breast tumors 
from obese patients. Assuming a hyperinsulinemic context related to obesity, p53 mutation 
would increase proliferation and dissemination of such tumors by promoting insulin-induced 
AKT activation. 
Regarding the possible implications of this observations, our group in previous studies designed 
an interfering GFP fusion protein, or decoy, capable of displacing the mutant p53-DAB2IP 
interaction; in tissue culture and in mouse xenografts, this decoy could efficiently reduce the 
invasive behavior of cancer cells exposed to inflammation (Di Minin et al., 2014). Here, we 
verified that such decoy can also efficiently inhibit insulin-induced cell proliferation and 
invasion.  
These results provide a crucial proof of principle that peptide or nucleotide aptamers designed to 
interfere with the mutant p53/DAB2IP interaction might have a potential application in targeted 
therapy of mutant p53 cancers. In particular, they point out the possibility to recover DAB2IP 
suppressive action on insulin-induced oncogenic phenotypes in cancers with mutant p53. 
 
In conclusion, the data presented in this Thesis uncover a molecular mechanism by which 
mutation of p53 might change the behavior of cancer cells exposed to insulin, suggesting a novel 
perspective for clinical management of obese, hyperinsulinemic patients. 
These data also provide yet another indication that, for those tumors where p53 is mutated, 
pharmacologic efforts aimed to tackle the gain of function of p53 bear a strong therapeutic 
potential. 
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 MATERIALS AND METHODS 
 
 Cell Culture, Transfections, Retroviral Transductions and drug treatments. 
The following cell lines were used: breast cancer MDA-MB-231 (p53R280K) and HBL-100 (wt 
p53), prostate cancer DU-145 (p53V274F/P223L), H1299 (p53 null), HEK 293GP (wt p53) and 
Ras-immortalized mouse embryonic fibroblasts (MEF) derived from p53 knock-out and 
p53R172H knock-in mice. MDA-MB231, HBL-100, HEK 293 GP and MEF were cultured in 
DMEM medium (Sigma) supplemented with 10% FBS (ECS0180L, Euroclone), and antibiotics 
(DE17-602E, Lonza). DU145 and H1299 cells were cultured in RPMI medium (Sigma) 
supplemented with 10% FBS and antibiotics. All cell lines were subjected to STR genotyping 
with PowerPlex 18D System and confirmed in their identity comparing the results to reference 
cell databases (DMSZ, ATCC, and JCRB databases), where possible. MEFs were collected from 
13.5 d.p.c. embryos of p53 knock-out and p53R172H knock-in mice, and immortalized by 
retroviral transduction of H-RasV12 (1). Transfections of H1299 were performed with 
Lipofectamine 2000 (Invitrogen), following manufacturer’s instructions. For siRNA 
experiments, cells were transfected with 50 nM siRNA oligonucleotides using Lipofectamine 
RNAiMax (Invitrogen), following manufacturer’s instructions. After 48 hr of silencing, Cells 
were processed after 48 hours, unless when differently specified. 
 
Sequence of siRNAs used: 
siRNA Sequence Purchased from 
Control siRNA Unknown All star negative control 
(1027281, Qiagen). 
sip53 ORF GACUCCAGUGGUAAUCUAC Eurofins MWG 
siDAB2IP A GGAGCGCAACAGUUACCUG Eurofins MWG 
siDAB2IP B GGUGAAGGACUUCCUGACA Eurofins MWG 
siDAB2IP 3’UTR GUAAUGUAACUAUCUCACC Eurofins MWG 
 
For retrovirus production, low confluency HEK 293GP packaging cells were transfected by 
calcium phosphate precipitation. After 48–72 hr the virus-containing medium was filtered and 
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added to target cells. Cells were selected with blasticidin (2 µg/ml) and/or puromycin (0.5 
µg/ml) and kept under selection for the entire experiment. Expression plasmids and retroviral 
constructs encoding DAB2IP, mutant p53 variants, and the eGFP-KA2 decoy construct have all 
been described previously (15). pcDNA3-flag-HA-AKT1 and was a gift from W. Sellers 
(Addgene plasmid # 9021). pcDNA3-Hygro-HA-AKT2  was a gift from M. Birnbaum (Addgene 
plasmid # 16000). pCMV6-p85alpha-Flag was a gift from L. Cantley (Addgene plasmid # 1399). 
For insulin treatment, cells were serum-starved for 24 h before addition of 0.5µg/ml human 
recombinant Insulin (Sigma, I2643). The AKT inhibitor MK2206 (Santa Cruz) was used at 5µM. 
 
BrdU incorporation assay 
For BrdU incorporation assay, cells were serum starved for 24 hr and after treated with 
insulin(0.5ug/ml) for 24 hr. Proliferating cells were labeled with 20uM 5'-bromo-2'-deoxyuridine 
(BrdU) in vitro for 2hr. Cells were fixed in 4% paraformaldehyde at room temperature, 
permeabilized in PBS plus 0.1% Triton X-100, and washed with NaOH (50 mM). Permeabilized 
cells were incubated with specific monoclonal antibody (GE Healthcare), followed by Alexa 
Flour® 568 conjugated secondary antibodies (Life Technologies). Nuclei were stained with 
Hoechst. Proliferating cells were scored by counting BrdU positive over total cell nuclei, in 25 
random microscope fields (at least 100 cells were counted per each sample). The total number of 
BrdU-labeled cells was counted directly under a Leica DM4000B epifluorescence microscope. 
 
Crystal violet cell proliferation assay 
Cells were seeded in a 96-well plate at a density of 5000 cells/well., grown in serum-fee medium 
for 24h and treated with insulin (0.5 ug/ml) for additional 24h and 48h. Subsequently, cells were 
fixed in 4% PFA and stained with 0.05% Crystal Violet. Wells filled with only medium provided 
the background absorbance of the dye. Optical density of each well was measured at 570 nm 
(OD570) with an Enspire multimode plate reader (PerkinElmer).  
 
Colony formation assay 
Cells were seeded at a density of 5000 (MDA-MB-231) or 3000 (DU-145) cells per 6 cm 
diameter plate, and incubated for 24 hours in 10% FBS-supplemented DMEM culture medium. 
Cells were then treated with insulin (0.5 ug/ml) every 48 hours. After 10 days, cells were fixed in 
4% PFA and stained with Giemsa (Sigma) for 2 hours. Plates were photographed and colonies ≥ 
50 pixels were counted using ImageJ software after background subtraction (2). 
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Matrigel invasion Assays 
Cells were grown in serum-fee medium for 24h and treated with insulin for additional 24h. 
Subsequently, cells were trypsinized, counted, and plated in 24-well PET inserts (8 µm pore size, 
Falcon), coated with BD Matrigel (BD Bioscience). The lower chamber was filled with high 
serum medium (10% FBS) without insulin. After 16h, cells passed through the filter were fixed 
in 4% PFA, stained with 0.05% crystal violet, and counted. Invasion was scored by counting 
cells in 22 random non-overlapping microscope fields at 40X magnification.  
 
RNA expression analysis 
Total RNA was extracted with QIAzol (QIAGEN). For RT-qPCR, 1 ug of total RNA was 
reverse transcribed with QuantiTect Reverse Transcription kit (QIAGEN). Real-time PCR was 
performed using SsoAdvanced SYBR Green Master Mix (Biorad) on a CFX96 Real-Time PCR 
System (Biorad). Primer sequences were as follows: 
 
INSR A/B Forward 5’-CAG CGA GAA ACT GCA TGG T-3’ 
 Reverse 5’-CAT TGG ACA TGG TAG AGT CG-3’ 
IGF1-R Forward 5’-TCT GGC CGA CGA GTG GAG-3’ 
 Reverse 5’-CTC GGT AAT GAC CGT GAG CTT-3’ 
Histone H3  Forward 5’-GAA GAA ACC TCA TCG TTA CAG GCC TGG T-3’ 
 Reverse 5’-CTG CAA AGC ACC AAT AGC TGC ACT CTG GAA- 
3’ 
 
 
Protein expression analysis 
Total cell extracts were prepared in RIPA buffer without SDS (150mM NaCl, 50mM Tris-HCl 
pH8, 1mM EDTA, 1% NP-40, 0.5% Na-deoxycholate) supplemented with 1 mM PMSF, 5 mM 
NaF, 1 mM Na3VO4, 10µg/ml CLAP, 1µM TSA and 5µM nicotinamide. Protein concentration 
was determined with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Lysates were 
resolved by SDS/PAGE and transferred to nitrocellulose (Millipore). 
Western blot analysis was performed according to standard procedures. When blots were probed 
with multiple antibodies, either proteins had markedly different electrophoretic migration, or 
were detected with primary antibodies raised in different species; in the latter case, signals from 
previous secondary antibodies were extinguished by sodium-azide treatment. When proteins 
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could not be detected on the same blot, a second gel was run in parallel with exactly the same 
amount of lysate. 
 
 
 
List of primary antibodies used: 
Target Antibody 
P53 (DO1) sc-126 (Santa Cruz) 
P53 (DO-7) DAKO 
Actin #A9718 (Sigma) 
AKT1 #2967 ( Cell Signaling) 
p-AKTS473 #9271 ( Cell Signaling) 
p-AKT S473 #4060 ( Cell Signaling) 
p-AKT T308 #9275 ( Cell Signaling) 
p-GSK3β S9 #9323 ( Cell Signaling) 
GSK3β #9832 ( Cell Signaling) 
CyclinD1 #2926 (Cell Signaling) 
c-Myc (9E10) Sc-40 ( Santa Cruz) 
p-p70 S6 kinase T421/S424 #9204 ( Cell Signaling) 
p-S6RP S235/236 #2211 ( Cell Signaling) 
S6RP #2217 ( Cell Signaling) 
HA(Y11) Sc-805 ( Santa Cruz) 
FLAG M2 F3165 (Sigma) 
GFP self-produced rabbit polyclonal 
DAB2IP A302-440A (Bethyl) 
p-P44/42 MAPK (ERK1/2) T202/Y204 #9101 (Cell Signaling) 
P44/2 MAPK (Erk1/2)  #9107 ( Cell Signaling) 
 
 
Protein interaction studies. 
For co-immunoprecipitation, expression plasmids were transfected in human H1299 cells. 24 hr 
after transfection cells were lysed in Co-IP buffer (NaCl 120mM, Tris-HCl pH7.5 20mM, EDTA 
1mM, NP40 0.5%) with protease inhibitors. Samples were cleared by centrifugation for 30 min 
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at 13000g at 4 °C and incubated overnight at 4 °C with specific antibody. After 1 hr incubation 
with protein G-Sepharose (GE Healthcare), immunoprecipitates were washed three times in Co-
IP buffer, resuspended in sample buffer, and analyzed by immunoblotting. Mouse IgGs were 
used as negative control. 
 
Immunohistochemical analysis 
A cohort of 52 cases of TNBC, including 32 from obese patients (BMI>30) and 20 from non 
obese patients (BMI <30), were collected from the Department of Pathology of National Cancer 
Institute “Fondazione G. Pascale”, Naples. All cases were reviewed according to WHO 
classification criteria, using standard tissue sections and immunohistochemical analysis. 
Informed consent for the scientific use of biological material was obtained from all patients.  ER 
status, PR status, and HER2 status had been routinely recorded at the hospital. 
Immunohistochemical staining on formalin-fixed, paraffin-embedded tumor tissue was 
performed on slides (4 μm) in order to evaluate expression of p53 (DO-7, DAKO) and p-
AKTS473 (sc-4060, Cell Signaling). The endogenous peroxidase activity was blocked by 
incubating the sections with about 150 μl of Novocastra Peroxidase Block (RE7101; 3% H2O2 ) 
for 10 min at room temperature, followed by 2 washes (5 min/each) in TBS/Tween buffer. The 
formation of non-specific binding between the antibodies and endogenous proteins was reduced 
by incubating the sections with about 150 μl of Novocastra Protein Block (10% FBS) for 20 min 
at room temperature, followed by 2 washes (5 min/each) in TBS/Tween buffer. After protein 
block, slides were incubated with about 150 µl of primary antibodies for over night at 4°C, 
followed by two washes in TBS/tween buffer (5 min/ each), secondary antibody (Novocastra 
Streptavidin- HRP, Leica Microsystems, Milan, Italy) for 40 min at room temperature, two 
washes in TBS/Tween (5 min/ each) and then visualized using a 3,3′-diaminobenzidine. The 
following negative controls were performed: (a) omission of the primary antibody; (b) 
substitution of the primary anti-serum with non-immune serum diluted 1:150 in blocking buffer; 
no immunostaining was observed in both cases. Sections were counterstained with 
hematoxylin/eosin and mounted. Stained tissue sections were evaluated independently by two 
clinical pathologists using uniform criteria. Discrepancies were resolved through simultaneous 
inspection and discussion of the results.  
Samples were scored as “mutant p53” when positive nuclear and cytoplasmic p53 staining was 
detectable in > 80% of tumor cells (3). Samples were scored as “p-AKT positive” when distinct 
cytoplasmic staining was detected in > 15% of tumor cells (4). For non-parametric analysis, the 
actual percentage of cells with distinct cytoplasmic p-AKT staining was used. 
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Statistical analysis 
In all graphs data are expressed as mean ± SEM of at least three independent experiments, except 
when otherwise indicated. Differences were analyzed by Student’s t test using Prism 5 
(GraphPad). P-values < 0.05 were considered significant. Immunohistochemical data were 
analyzed using SPSS 17.0 software (Inc., Chicago, Ill., USA); both the Mann-Whitney non-
parametric test and the Pearson’s chi-square parametric test were used to evaluate correlations 
between p53 mutation and p-AKT(S473) expression. 
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